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Chapter I 
 
INTRODUCTION 
 
Metabolic Homeostasis: Skeletal Muscle as a Key Metabolic Organ 
The incidence of metabolic syndrome in the U.S. is on the rise with 
approximately 34% of the adult population meeting the criteria (1). Metabolic syndrome 
is a grouping of risk factors for the development of cardiovascular disease including three 
or more of the following: abdominal obesity, low HDL cholesterol, high triglycerides, 
raised blood pressure, and insulin resistance. The rise in metabolic syndrome is, in part, 
due to the increased diagnosis of type 2 diabetes and insulin resistance. Nearly 26 million 
people in the U.S. have diabetes and an alarming 79 million adults currently live with 
prediabetes (insulin resistance) (2). Insulin resistance and metabolic syndrome are 
multifactorial health issues that involve the potential interaction between lifestyle 
characteristics such as diet and physical activity level, obesity, genetic predisposition, 
chronic inflammation, elevated free fatty acids, mitochondrial dysfunction, and 
impairments in insulin signaling (3). Diabetes is the seventh leading cause of death due to 
increased risk for heart disease and stroke (2). 
Skeletal muscle is the primary site of action for insulin-stimulated glucose 
disposal. β-cells respond to postprandial hyperglycemia to secrete insulin into the 
circulation, which acts on peripheral tissues. The liver is responsible for approximately 
30% of postprandial glucose clearance while the periphery responds to the circulating 
insulin to stimulate skeletal muscle glucose uptake (MGU), thus promoting a return to 
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euglycemia (4-7). Furthermore, DeFronzo et al. demonstrated that skeletal muscle is the 
primary site of glucose disposal during hyperinsulinemic-euglycemic clamps 
corresponding to 80% of whole body glucose uptake and this response is blunted in 
diabetic subjects (8). Prediabetic and type 2 diabetic patients have an impaired response 
to insulin to stimulate MGU causing extended or unresolved hyperglycemia after a meal. 
Skeletal muscle insulin resistance is present prior to an overtly elevated fasting plasma 
glucose and a diagnosis of type 2 diabetes (5). There is an association between factors of 
metabolic syndrome and insulin resistance. Patients with essential hypertension and 
ischemic heart disease have a 35-50% decrease in insulin-stimulated glucose disposal (9, 
10).  The majority of hypertensive patients are either insulin resistant or diagnosed type 2 
diabetics suggesting a clear link between vascular and metabolic function in obese 
populations (11). The action of insulin to promote vasodilation and enhance skeletal 
muscle perfusion is a potential link between insulin resistance and vascular disease. 
However, the exact mechanisms for the pathogenesis of skeletal muscle insulin resistance 
are not fully elucidated and further studies are required to corroborate the potential 
interplay between vascular and metabolic dysfunction that could result in novel treatment 
targets for metabolic syndrome.  
 
Skeletal Muscle Perfusion: A Critical Component of In Vivo Insulin-Stimulated 
Muscle Glucose Uptake 
The ability of insulin to stimulate glucose disposal is principally regulated by 
skeletal muscle glucose influx (12). The control of MGU is distributed between 3-steps, 
as depicted in Figure 1 (13, 14).  To elucidate the resistances to glucose flux through the 
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three steps an in vivo model must be employed due to the complex regulation of fluxes 
via multiple organ systems. 
 
Figure 1.1 - Distributed Control of Muscle Glucose Uptake – Representation of the 
three step process of muscle glucose uptake and the contributing factors of each 
component  
 
Furthermore, in vivo glucoregulatory analysis is best studied under well-controlled 
conditions where the subject is conscious, unstressed, and arterial glucose levels are 
clamped. The clamping of glucose concentration prevents activation of compensatory 
hormone or autoregulatory systems. For example, clamping glucose at euglycemic levels 
averts hypoglycemia during an insulin infusion, which prevents the body from 
responding by increasing glucagon, corticosterone (in rodents), catecholamines, and other 
glucose counterregulatory factors. Also, in vivo glucose flux analysis is optimally 
performed in conscious animals because anesthesia decreases metabolism and hormone 
sensitivity. By utilizing the Vanderbilt Hyperinsulinemic-Euglycemic Clamp Method 
(insulin clamp) we are able to determine muscle glucose influx without the concerns 
delineated above or inducing a stress response from handling of mice (15, 16).  In vivo 
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metabolic studies facilitate the comprehensive understanding of how an experimental 
factor (e.g. increase in fat mass) affects MGU. Cell culture and ex vivo models remove 
the delivery component of MGU and require supraphysiological levels of insulin to 
stimulate glucose uptake. As a result, these experimental models isolate the glucose 
transport and phosphorylation components of insulin-stimulated MGU, but exclude the 
extramyocellular factors that contribute to insulin action.  
To understand the integrated regulation of MGU that occurs in a physiological 
state the three steps must be present in the experimental model. Glucose delivery is 
regulated by arterial concentration and perfusion of the muscle bed. Muscle blood flow is 
controlled by capillary recruitment and total blood flow in response to insulin stimulation 
(step 1). At the muscle interstitium glucose is transported across the sarcolemma 
membrane by GLUT4 after translocation to the membrane in response to myocellular 
insulin signaling events (step 2).  Intramyocellular glucose is phosphorylated to glucose-
6-phosphate, which is regulated by hexokinase activity and compartmentation (step 3). 
Glucose phosphorylation is the terminal step of MGU as muscle lacks glucose-6-
phosphatase activity trapping phosphorylated glucose in muscle. In the fasted state, 
control of MGU is at the transport step due to the low number of GLUT4 at the 
sarcolemma membrane rendering the muscle impermeable to glucose (17). Utilizing the 
principles of glucose countertransport, Halseth et al. showed that the transport barrier is 
minimal during insulin stimulation due to the muscle being highly permeable to glucose 
after GLUT4 insertion into the membrane. The control of insulin-mediated MGU is 
distributed between glucose delivery and phosphorylation (18-20).  
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Fueger et al. further defined the barriers to MGU utilizing genetic mouse models 
to functionally remove the transport barrier by overexpression of GLUT4, the 
phosphorylation barrier with hexokinase II overexpression, or the combination of both 
proteins (17). Data collected from insulin clamp studies in these mouse models support 
the conclusions of the countertransport studies of Halseth et al. (18). Fueger et al. applied 
control theory to determine the functional barriers to MGU (21): CTg = Δln(Rg)/Δln(PTg) 
where CTg is the control coefficient, Rg is the index for MGU, and PTg is the level of 
hexokinase II or GLUT4 relative to controls. The assumptions in this model are twofold; 
MGU is a defined pathway in which the sum of the control coefficients for each MGU 
equals 1 and the increase in protein expression directly correlates to its activity. As 
shown in Table 1.1, the primary barriers to MGU during insulin stimulation are delivery 
and phosphorylation.  
 
Control Step Delivery Transport Phosphorylation 
Rest 0.1 0.9 0.0 
Insulin Clamp; 4 mU·kg
-1
·min
-1
 0.5 0.1 0.4 
Table 1.1 - Control Coefficients for Muscle Glucose Uptake – Control coefficients for 
each component of muscle glucose uptake at rest and during insulin stimulation in lean 
mice 
 
The countertransport and genetic models emphasize the importance of glucose delivery 
during insulin-stimulated MGU. Glucose delivery is dependent on arterial concentration, 
which is regulated by nutrient absorption by the gut, liver glucose output in addition to 
the action of insulin to enhance muscle perfusion. Glucose delivery augments the 
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myocyte exposure of glucose by mass action down the glucose concentration gradient 
from the plasma to muscle interstitium.  
Any factor that causes changes in MGU, whether it is a characteristic of health or 
disease, works through one of these three steps. For example, skeletal muscle 
accumulation of glucose-6-phosphate reduces MGU by regulating glucose 
phosphorylation through negative feedback inhibition of hexokinase activity. 
Furthermore, the delivery component of MGU does not rest only on glucose movement 
from the vascular to muscle compartment. The delivery of arterial insulin to the 
interstitium of skeletal muscle is the rate-limiting step for the onset of insulin-stimulated 
MGU, suggesting the importance of insulin delivery to MGU (22).  
The metabolic action of insulin at skeletal muscle is limited by its transport from 
the plasma compartment to the interstitial compartment (23). Investigation by the 
laboratory of Olefsky extensively demonstrated the delayed onset of insulin action and 
insulin receptor kinase activation in skeletal muscle (24-26). During insulin clamps in 
healthy human subjects the half-maximal plasma insulin levels occurs between 4.9-7.2 
min with corresponding half-maximal glucose disposal rate and insulin receptor kinase 
activation between 40-60 min (24). Furthermore, obese subjects have a much slower 
onset of peripheral glucose disposal compared to healthy controls. Notably, there was no 
difference in the time to reach half-maximal suppression of hepatic glucose production 
(~20 min) in obese subjects, which is likely due to differences in microvascular structure 
(e.g. the liver has discontinuous capillaries and muscle has tight capillaries) and the high 
liver perfusion causing a more rapid appearance of insulin (26). The blood flow to the 
liver is homogenous and 33-fold higher at rest than skeletal muscle, which in congruence 
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to the leaky capillary structure permits much higher insulin extraction (27). Nolan et al. 
further demonstrated that the diabetic patients had a marked delay in the activation of 
glucose disposal and leg glucose uptake when comparing obese patients to diagnosed 
type 2 diabetics (25). Bergman and colleagues showed that the concentration of 
interstitial and lymph insulin correlates more closely to the onset of glucose disposal than 
the rise in plasma (28-30). The importance of insulin appearance at the muscle 
interstitium was confirmed by studies that directly injected skeletal muscle of dogs with 
insulin and showed an immediate stimulation of MGU (31).  
The architecture of the capillary wall within skeletal muscle determines the 
transport and delivery capacity of large molecules such as insulin. Skeletal muscle 
capillaries are characterized by tight junctions and an enrichment of caveolae number 
(27). King and Johnson were the first to propose that insulin moves across the endothelial 
layer in a receptor-mediated mechanism (32). This finding was supported by in vivo 
evidence. Wang et al. obtained serial muscle biopsies while performing an insulin clamp 
with FITC-labeled insulin and demonstrated that the labeled insulin was bound to the 
endothelium but was yet to be transported to the muscle interstitium 10 min after the 
outset of the clamp (33). Wang and Barrett further showed the co-localization of the 
labeled insulin with the insulin receptor and caveolin-1 on the luminal membrane of 
endothelial cells (33). The transport potential of the endothelium is dependent on the 
activation and downstream signaling of the endothelial insulin receptor.  The transport of 
insulin is impaired with  exposure to inflammatory cytokines such as TNFα and with 
knockdown of the caveolin-1 protein, which is critical to the formation of caveolae (34). 
However, the in vivo effects of diet-induced insulin resistance on skeletal muscle 
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capillary transport capacity of insulin and whether structural changes occur that could 
alter the transport potential is unknown.  
Obesity is a major risk factor for cardiovascular morbidity and mortality that 
associates with the development of insulin resistance at tissues such as skeletal muscle, 
liver, and adipose tissue. A deficit at any of the three steps to MGU can cause insulin 
resistance. In animal models of obesity impairments in the action of insulin to augment 
muscle blood volume (35-38), glucose sarcolemma transport (39-41), and glucose 
phosphorylation can be present (42, 43).  However, in high fat-fed rats the primary deficit 
in insulin-stimulated MGU is in the delivery component (18). The hemodynamic action 
of insulin to increase muscle blood volume is blunted in obesity supporting the paradigm 
that the delivery step of MGU is critical to  the etiology of skeletal muscle insulin 
resistance (35, 36, 44). 
 
Loss of Vascular Function 
The initiation of skeletal muscle insulin action is dependent on the appearance of 
interstitial insulin. The transcapillary delivery of insulin to muscle is rate-limiting in 
healthy subjects and is delayed in insulin resistant patients (23). Insulin acts on the 
vascular tree to enhance its own delivery by relaxing resistance arteries and arterioles to 
augment total limb blood flow, relaxing precapillary arterioles to recruit unperfused 
capillaries thus increasing the surface area for substrate exchange, and enhancing 
capillary vasomotion to enhance blood flow distribution (23, 45, 46). The hemodynamic 
actions of insulin precede insulin-stimulated MGU. Bergman et al. demonstrated that in 
vivo insulin injection directly into skeletal muscle immediately induces MGU, supporting 
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the hypothesis that insulin delivery is a significant barrier to the onset of insulin-
stimulated MGU (31). 
The increase in capillary blood volume occurs within minutes of insulin 
administration with a delayed increase in total limb blood flow (45). Ellmerer et al. 
showed that insulin augments macronutrient delivery to skeletal muscle during an insulin 
clamp and appearance of macromolecules in skeletal muscle lymph, a surrogate for the 
interstitium, is diminished in obese dogs (47). Moreover, the presence of the endothelial 
insulin signaling machinery is essential for the vascular actions. The significance of 
insulin and glucose delivery to tissue glucose uptake is specific to muscle. The structure 
of the endothelium in muscle is continuous, which contrasts with the discontinuous 
endothelial barrier of liver and the blood flow to the liver is naturally high in the basal 
state (27, 48). Insulin resistance occurs at the level of large arteries and the 
microcirculation that prevents the rise in skeletal muscle perfusion during insulin 
stimulation (49, 50). Structural and functional capillary rarefaction contribute to the 
blunted muscle blood volume during insulin stimulation. Structural capillary rarefaction 
is the attenuation in capillary to myocyte ratio and functional capillary rarefaction is the 
impairment in endothelial function preventing arterial relaxation at sites of resistance. 
Structural and functional capillary rarefaction develops in insulin resistant patients and 
experimental models of type 2 diabetes (36-38, 44, 49, 51-57).  
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Figure 1.2 - Capillary Density in Healthy and Insulin Resistant Muscle – Insulin 
resistant subjects have decreases in the number of capillaries perfusing skeletal muscle 
compared to healthy controls 
 
The abnormal vascular responses to insulin diminish the surface area available for 
insulin and glucose exchange exacerbating the insulin resistant phenotype. Benedict et al. 
performed a complex analysis of the capillary network connectivity and structure in 
Zucker diabetic fatty rats before and after the onset of type 2 diabetes. After the 
development of insulin resistance, there was a 37% decrease in capillary branching and a 
44% decrease in capillary flow per muscle compared to non-diabetic controls (49). This 
large deficit in functional capillary reserve limits the action of insulin to augment 
microvascular blood volume. Moreover, a graded occlusion of  skeletal muscle capillaries 
with 15µm diameter microspheres, in a healthy perfused hindlimb, is sufficient to impair 
muscle insulin action supporting the importance of the skeletal muscle capillary reserve 
(58). However, it is currently unknown whether structural capillary rarefaction is critical 
to the pathogenesis of muscle insulin resistance. 
11 
 
Functional capillary rarefaction contributes to the deficit in insulin-stimulated 
muscle perfusion. Inhibiting the action of insulin to recruit unperfused capillaries impairs 
insulin-stimulated glucose disposal (59). Multiple experimental techniques, such as 1-
methylxanthine metabolism and contrast enhanced ultrasound, permit the characterization 
of the effect of insulin to rapidly recruit unperfused capillaries, thus increasing skeletal 
muscle blood volume (23, 45, 60).  Endothelial dysfunction in large arteries parallels the 
deficit in capillary recruitment contributing to the overall decrease in skeletal muscle 
perfusion (61). A large systemic review and meta-analysis showed that markers of 
vascular dysfunction strongly associate with type 2 diabetes. Specifically, this 
comprehensive review determined that plasma soluble adhesion molecules, vascular 
reactivity, arteriole to venule ratio, and microalbuminuria (all markers of vascular 
dysfunction) correlate to the presence of type 2 diabetes in patients (62). Vincent et al. 
determined that inhibiting insulin-induced activation of nitric oxide synthase (NOS) 
attenuates glucose disposal by 30-40% (59). Extending this concept, subjects with the 
greatest muscle blood volume have the greatest glucose disposal during an insulin clamp 
even in healthy, normotensive, and non-obese subjects (63). Vascular dysfunction is an 
important risk factor for cardiovascular mortality, which is the leading cause of death in 
diabetic patients (64). Vascular dysfunction may be a common characteristic linking the 
co-prevalence of cardiovascular and metabolic diseases. 
The binding of insulin to the endothelial insulin receptor initiates a PI3-kinase-
dependent pathway similar to other insulin responsive tissues. Activation of endothelial 
insulin signaling causes Akt-mediated phosphorylation of endothelial NOS (eNOS) that 
stimulates nitric oxide synthesis and vasodilation (46). Insulin concurrently activates the 
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mitogen-activated protein kinase pathway, which increases the expression of the 
vasoconstrictor endothelin-1 (ET-1); however, in healthy subjects the eNOS pathway 
dominates (46, 65). The endothelium is characterized by pathway selective insulin 
resistance in obesity blunting PI3-kinase activation and promoting ET-1 production 
resulting in further endothelial dysfunctional (66).  
 
 
Figure 1.3 - Endothelial Insulin Signaling in Health and Disease – The vasodilatory 
and capillary recruitment actions of insulin occur via the canonical insulin receptor 
pathway in endothelial cells, which is defective in insulin resistant states 
 
Pharmacologically or genetically eliminating eNOS activation in the presence of 
insulin diminishes glucose disposal and skeletal muscle perfusion (67, 68). Kubota et al. 
characterized the essential role of endothelial insulin signaling to MGU. The 
enhancement in skeletal muscle perfusion during an insulin clamp is abolished in obese 
and IRS-2 deficient mice, the primary endothelial isoform (48). Both mouse models have 
decreased insulin-mediated eNOS activation, insulin delivery to skeletal muscle 
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interstitium, and MGU. In diet-induced insulin resistant animal models, the deficit in 
vascular insulin signaling precedes the onset of peripheral insulin resistance, suggesting 
that the endothelium is more susceptible to dietary fat ingestion (50). Moreover, activity 
restriction in lean non-human primates impairs microvascular function and induces 
insulin resistance providing a potential link between obesity and physical inactivity to the 
pathogenesis of insulin resistance (69). This vascular detriment is an early and likely a 
causative factor for the development of skeletal muscle insulin resistance.  
 
VEGF-Dependent Angiogenesis 
Vascular endothelial growth factor-A (VEGF) is essential for the coordinated 
development of the vascular system during embryonic maturation and angiogenesis in 
adult animals. Notably, global deletion of a single VEGF allele is sufficient to cause 
embryonic death (70-72). Eukaryotic organisms have a family of VEGF proteins, listed in 
Table 1.2, that regulate vasculogenesis, angiogenesis, and lymphanogenesis. VEGF binds 
primarily to two receptors, VEGFR1 and R2. The angiogenic action of VEGF is mediated 
through VEGFR2. The role of VEGFR1 is less characterized and considered to be anti-
angiogenic, in particular soluble VEGFR1. VEGFR1 has a high affinity for VEGF 
sequestering it from VEGF2 interaction and the induction of angiogenesis. VEGF action 
is essential for the adaptive response to changes in substrate demand. For example, 
increases in oxygen and energy demands during exercise stimulates the growth and 
branching of tissue capillaries to increase the surface area for substrate and waste 
exchange in metabolically active tissues. VEGF induces chemotaxis and differentiation 
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of endothelial precursor cells, endothelial cell proliferation, the assembly of endothelial 
cells into the vascular network, and remodeling (73) 
 
Table 1.2 - VEGF Isoforms, Receptors, and Physiological Actions – VEGF-A 
is the critical isoform that regulates angiogenesis and microvascular density  
 
There is an augmentation of skeletal muscle VEGF expression during exercise in 
response to the increase in energy demand (74). Skeletal muscle adapts to the greater 
oxygen and substrate requirements to increase capillary density, and thus, muscle 
perfusion. Tang et al. demonstrated that skeletal muscle VEGF deletion causes capillary 
rarefaction characterizing the critical role of VEGF in the maintenance of muscle 
capillary density (75, 76). In accordance with the results in skeletal muscle, Giordano et 
al. discovered that the deletion of VEGF in cardiac muscle induces fewer capillaries 
perfusing the heart (77). These studies describe the importance of paracrine VEGF 
signaling from the muscle to the endothelium to sustain tissue capillary requirements. 
This contrasts with endothelial specific VEGF expression that is necessary for endothelial 
cell integrity and survival via an autocrine signaling mechanism (78).  
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There is impairment in VEGF action in diabetic patients that causes capillary 
rarefaction and a blunted adaptive response to increases in metabolic demand (79-83). 
Animal models of diabetes develop cardiomyopathy due to a progressive loss of 
myocardial VEGF expression (81). In peripheral and cardiac ischemia, diabetic animals 
and patients are unable to induce collateral vessel growth to ameliorate the hypoxic event 
(79, 82). The detriment in angiogenesis worsens outcomes in diabetic patients leading to 
increase mortality after an ischemic event compared to non-diabetics.  
 
Gain of Vascular Function 
Modulation of skeletal muscle perfusion impacts MGU as described in equation 1 
for the calculation for MGU:  
                     
Femoral            is the arterial-venous difference across the muscle of interest and 
     is the total blood flow to that muscle. Baron et al. showed that limb blood flow 
independently modulates femoral glucose uptake (84). Baron and colleagues performed 
insulin clamps on lean subjects and determined glucose uptake during steady-state period 
(equation 1). The investigators next increased blood flow with metacholine, a NO 
dependent vasodilator. The study determined that elevating blood flow during steady-
state hyperinsulinemia augments femoral glucose uptake (84). This seminal result 
showed the significance of modulating blood flow to enhance insulin-mediated MGU and 
highlighted the importance to consider muscle perfusion in the treatment of insulin 
resistance.  
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Baron and colleagues furthered defined the influence of muscle blood flow in type 
2 diabetic patients. In this study, the authors performed a constant insulin infusion at 
120mU/m
2
·min
-1
 in diabetic and healthy subjects with glucose concentrations clamped at 
incremental levels. At all steady-state glucose concentrations there was no change in 
femoral ΔAVglucose; however; limb blood flow was significantly lower at each glucose 
step in the diabetic patients and plateaued at a lower glucose concentration resulting in 
the lower limb glucose uptake (36). These results indicate that reduced glucose and 
insulin delivery to skeletal muscle is critical to the pathogenesis of diabetes. Moreover, 
large artery dysfunction correlates to the state of metabolic impairment evident in obese, 
type 2 diabetics (27). The permeability surface area for glucose during insulin 
stimulation, a measurement of the capacity for glucose to reach the interstitial fluid, in 
forearm muscle is impaired in obese insulin resistant subjects compared to obese insulin 
sensitive controls. This deficit that can be overcome by co-infusion of a vasodilator (85).  
 The diseased vasculature associated with insulin resistance and type 2 diabetes 
provides an important pharmacological target to comprehensively treat the metabolic 
syndrome. Murdolo et al. demonstrated that an acute infusion with the vasodilator 
metacholine, during hyperinsulinemia, improves the delayed onset of insulin action at 
skeletal muscle present in insulin resistant subjects (85). It is important to note that this 
study was performed in an acute setting and without focus on intervention to treat muscle 
insulin resistance. Our laboratory investigated the effects of inhibiting cGMP breakdown 
using the phosphodiesterase-5 inhibitor sildenafil at the onset and duration of diet-
induced insulin resistance (86). Nitric oxide rapidly diffuses from the endothelium to 
smooth muscle stimulating cGMP synthesis by soluble guanylate cyclase, the secondary 
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messenger necessary for NO-mediated vasodilation. Ayala et al. demonstrated the 
protective effect of pharmacologically targeting the vasculature at the outset of a high fat 
(HF) diet to prevent the development of skeletal muscle insulin resistance (86). While 
this study provided evidence consistent with improved vascular function in the 
prevention of diet-induced insulin resistance, it was not designed to address the more 
clinically relevant issue of reversing insulin resistance. Kang et al. expanded on these 
studies to show that capillary density was greater in mice treated with sildenafil for the 
duration of an obesogenic diet, suggesting that the actions of sildenafil to maintain 
capillary density and muscle perfusion are important (87). Additionally, a study in 
fructose-fed rats showed that an intervention with an angiotensin II receptor inhibitor 
reverses skeletal muscle insulin resistance attributed to a normalization of capillary 
density compared to chow-fed controls (53). These studies support the concept that the 
vascular system provides novel and viable therapeutic targets to concomitantly treat 
metabolic and cardiovascular diseases that associate with the growing obesity epidemic. 
 
Relaxin: A Novel Therapeutic Agent with Possibilities to the Treatment of Diabetes 
The hormone relaxin was first discovered by Frederick Hisaw in 1926 and 
described as a hormone of pregnancy (88). Relaxin is now characterized as a critical 
hormone for the cardiovascular and renal adaptations during pregnancy. The pleiotropic 
actions of relaxin include systemic vasodilation to increase fetal nutrient delivery and 
enhanced renal function to accommodate higher demand for waste excretion (89). Recent 
clinical and animal data have expanded the cardiovascular actions of relaxin to males. 
Relaxin was originally described to belong to the insulin hormone superfamily due to the 
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6 kDa size of both peptides and disulfide bonds that are crucial for structural integrity. 
However, current data now suggests that relaxin diverged from the insulin family of 
proteins early in vertebrate evolution forming a specific relaxin peptide family (90). 
There are three unique relaxin genes in humans (RLN1, RLN2, and RLN3) that encode for 
H1, H2, and H3 relaxin respectively (90). In non-human primates there are only two 
relaxin genes (RLN1 and RLN3), in which the RLN1 gene corresponds to H2 relaxin.  The 
physiological actions described herein refer to H2 relaxin as relaxin. Relaxin is expressed 
in reproductive and non-reproductive tissues including uterus, prostate gland, brain, 
pancreas, kidney, and heart (91, 92). Relaxin acts through two G-protein coupled 
receptors RXFP1 and RXFP2, which contain leucine-rich repeats (93). Relaxin has a 
much higher affinity for RXFP1. RXFP1 is widely expressed and abundantly present in 
the reproductive, nervous, and cardiovascular systems in both male and female animals 
(93).  
The vascular effects of relaxin, inducing vasodilation and a decrease in systemic 
vascular resistance, are mediated by the endothelin system. The close proximity of the 
relaxin and the ET-1 signalosomes support this mechanism. ET-1 is synthesized by 
endothelial cells and processed to ET1-32, which specifically induces the vasodilatory 
actions of relaxin. ET-1 binds to the ETA and ETB receptors on vascular smooth muscle to 
cause vasoconstriction; however, the ETB receptor is present on endothelial cells and 
induces NO dependent relaxation (94). Relaxin increases matrix metalloproteinase 
(MMP) activity that regulates the processing of ET-1 and MMPs are required for the 
acute vasodilatory effects of relaxin (94). The in vivo actions of relaxin to alter vascular 
compliance are not fully understood. Specific mechanisms depend on the exposure time 
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such that the fast acting (minutes) response is dependent on components of RXFP1 
signaling directly, the intermediate response (hours) is primarily dependent on MMP-9 
activation, and the long-term (days) action of relaxin is dependent on both ET-1 and 
VEGF signaling mechanisms (95). Convergence on eNOS activation and NO synthesis is 
common between all three pathways.  
 
Figure 1.4 - Mechanisms of Relaxin Action – Physiology of relaxin that result in the 
anti-fibrotic, vasodilatory, and angiogenic actions and proposed to be important to 
intervene on the development of insulin resistance 
 
The physiological actions of relaxin are not limited to the cardiovascular effects. 
Relaxin decreases collagen biosynthesis and promotes collagen degradation. The 
regulation of connective tissue homeostasis promotes an anti-fibrotic environment. 
Relaxin inhibits transforming growth factor-β (TGFβ) signaling to prevent collagen 
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biosynthesis (96-99). Relaxin augments MMP expression and/or decreases expression of 
tissue inhibitor of metalloproteinase to enhance the activity of MMPs (100-103). 
Importantly, the anti-fibrotic action of relaxin occurs only in the presence of aberrant 
fibrosis and does not alter extracellular matrix proteins in healthy tissue.  Genetically 
engineered mice with RLN1 deletion corroborate the extracellular matrix remodeling 
characteristics of the hormone. Relaxin-deficient mice exhibit an age-induced increase in 
cardiac fibrosis compared to wild-type controls, and this phenotype was normalized after 
a 2 week relaxin intervention (103).  
The stimulation of VEGF expression is critical to the vasodilatory and angiogenic 
mechanisms of relaxin physiology (104, 105). Hisaw and colleagues first discovered the 
angiogenic role of relaxin showing the importance of relaxin for the increase in capillary 
density in the endometrium during pregnancy (106). Additionally, relaxin causes 
angiogenesis in a rat model for chronic myocardial infarction (107). This conclusion was 
further confirmed in a swine model of heart failure. In the swine model, Formigli et al. 
transfected myoblasts with the relaxin gene and grafted the cells into the post-infarcted 
heart. The transplanted relaxin expressing cardiomyoblasts increases VEGF expression in 
the endogenous myocardial cells to expand capillary density (108). The angiogeneic 
mechanism of relaxin is, in part, by acting on bone marrow derived endothelial cells 
(BMDEC) to mobilize and enhance homing to sites of angiogenesis (104). Relaxin acts 
via the RXFP1 receptor on BMDECs to increase NO synthesis, which is critical for 
function (104). This is an important discovery because many secreted factors that 
mobilize BMDEC to integrate into sites of angiogenesis are concurrently described as 
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inflammatory agents (e.g. granulocyte-colony stimulating factor), which differs from the 
actions of relaxin.   
The cardiovascular, angiogenic, and anti-fibrotic properties of relaxin make the 
hormone a promising candidate for intervention. The diverse actions of relaxin have 
provided enthusiasm and promise in several clinical disease states. There are ongoing 
clinical trials for the therapeutic application of relaxin. The first clinical trial to test the 
efficacy of relaxin was in scleroderma patients. In phase III trials relaxin decreased 
fibrosis of the skin, improved renal function, and decreased diastolic blood pressure, but 
the results were not considered clinically significant enough for market approval (109). 
The focuses of two current trials are pre-eclampsia and congestive heart failure. Pre-
eclampsia is a disorder in pregnant woman manifested by systemic vascular constriction 
resulting in the development of hypertension and impaired organ function, particularly of 
the kidney. The pathogenesis of pre-eclampsia is, in part, due to the endogenous 
inhibition of VEGF signaling. The goal of relaxin intervention is to alleviate 
hypertension, improve renal function, and maintain endometrial vascular capacity to 
accommodate the requirements for placental perfusion (109). The RELAX-AHF phase III 
clinical trial for congestive heart failure has shown encouraging results. Congestive heart 
failure is the most common reason for hospitalization of patients older than 65 years. 
These patients have a very poor prognosis attributable to end-organ dysfunction in heart, 
liver, and kidney. The vascular and anti-fibrotic actions of relaxin have potential to 
ameliorate these early clinical symptoms and extend long-term survival by promoting 
cardiac oxygen delivery and abating fibrosis. The RELAX-AHF clinical trial has shown 
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positive outcomes that indicate reduced cardiac, renal, and hepatic damage after the 
initial hospitalization and increased 180-day survival rate (110).  
The advantage of relaxin intervention is the unique property of the hormone to 
reverse disease pathology by invoking multiple systems and not affecting healthy tissue. 
Cardiovascular disease is the major risk factor for mortality in obese, diabetic patients. 
Furthermore, macro- and microvascular dysfunction in addition to collagen deposition 
associate with the development of insulin resistance and type 2 diabetes (62, 87, 111). To 
decrease the risk of cardiovascular disease in the obese population, it is critical to 
consider endothelial health in drug development. Endothelial health is important to organ 
metabolism and function. The endothelial cell layer was originally considered a simple 
physical barrier between the blood and perfused tissue; however, the endothelium is a 
functioning cell type important for tissue integrity. The functional properties of the 
endothelium are primarily regulated by eNOS activity and synthesis of NO. Our goal is to 
investigate the potential for relaxin to reverse the extramyocellular adaptations associated 
with a high fat (HF) diet to treat insulin resistance and cardiovascular dysfunction.  
 
Hypotheses 
The hypothesis investigated in the dissertation is that skeletal muscle vascular 
integrity is critical for skeletal muscle insulin action. More specifically, I propose that 
capillary rarefaction directly impairs insulin-stimulated MGU by creating a resistance to 
the delivery component of MGU, the vascular impairments induced by a HF diet are 
viable intervention targets to reverse muscle insulin resistance by removing the 
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resistance, and HF-fed mice have a decrease in caveolae density in skeletal muscle 
capillaries.  
 
 
Figure 1.5 - Hypotheses - Loss of Vascular Function (A) and Gain of Vascular 
Function (B) – Hypothesis A is designed to test whether a decrease in capillary density is 
sufficient, absent of any other insulin resistance-inducing factors, to cause muscle insulin 
resistance. Hypothesis B is designed to test whether targeting the extramyocellular 
adaptations to a HF diet - vascular dysfunction and capillary rarefaction - with the 
hormone relaxin reverses diet-induced skeletal muscle insulin resistance 
 
The goal of Aim 1 (Chapter III) is to determine whether capillary rarefaction is a 
cause or a consequence of muscle insulin resistance. To address Aim 1, mice with 
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muscle-specific genetic deletion of vascular endothelial growth factor-A were utilized to 
induce muscle capillary rarefaction in a lean mouse model. This model permits the 
investigation into the specific consequence of reducing capillary number to insulin-
stimulated MGU. I hypothesize that a genetic decrease in skeletal muscle capillary 
density by VEGF ablation will induce skeletal muscle insulin resistance in otherwise 
healthy mice.  
The goal of Aim 2 (Chapter IV) is to determine whether pharmacologically 
targeting the vasculature with the hormone relaxin rescues HF diet-induced muscle 
insulin resistance. To address Aim 2, lean C57BL/6J mice were first studied to determine 
the hemodynamic and metabolic effects of relaxin during a hyperinsulinemic-euglycemic 
clamp. To investigate the therapeutic potential of relaxin C57BL/6J mice were fed a HF 
diet for 13 weeks with the final 3 weeks of the diet mice received a continuous infusion 
of relaxin or vehicle via osmotic minipumps. I hypothesize that a chronic intervention of 
relaxin will reverse the extramyocellular adaptations to a HF diet thus ameliorating diet-
induced skeletal muscle insulin resistance.  
The goal of Aim 3 (Chapter V) is to determine whether microstructural changes to 
endothelial caveolae occur after 16 weeks of HF-feeding. Caveolae have been 
hypothesized to play a critical role in transendothelial insulin transport specifically in 
skeletal muscle microvasculature. To address Aim 3 C57BL/6J mice were fed a HF diet 
for 16 weeks or a low fat chow diet. Mice underwent perfused fixation to preserve in vivo 
microstructures of skeletal muscle capillaries for visualization by transmission electron 
microscopy. I hypothesize that a decrease in caveolae number within skeletal muscle 
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capillaries contributes to the etiology of skeletal muscle insulin resistance by increasing 
the delivery barrier for insulin.   
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Chapter II 
 
RESEARCH MATERIALS AND METHODS 
 
Mouse Models 
 The Vanderbilt University Animal Care and Use Committee approved all animal 
protocols. Mice were housed with a 12:12 h light-dark cycle in a temperature and 
humidity controlled environment. Mice with muscle-specific genetic deletion of VEGF 
were studied in Chapter III. Mice with LoxP sites flanking exon 3 of the VEGF gene 
(generously provided by Dr. Alvin Powers Laboratory) on a congenic background (112) 
and mice expressing Cre recombinase under the muscle creatine kinase (MCK) promoter 
(purchased from Jackson Laboratory) were crossed to generate the MCK-cre/VEGF
lox/lox 
(mVEGF
-/-
)
 
 mice and wild-type littermates VEGF
lox/lox 
(mVEGF
+/+
). Mice were 
backcrossed on to a C57BL/6 background for at least 10 generations. The MCK promoter 
is expressed in skeletal and cardiac muscle. mVEGF
-/-
 mice lack all VEGF-A isoforms. 
Female mVEGF
+/+ 
mice were mated with male mVEGF
-/-
 to prevent cardiac 
complications during gestation. Mice were weaned at 3 weeks of age and separated by 
sex. Mice were briefly anesthetized using isofluorane to obtain a sample of tail tissue for 
genotyping and to ear punch for identification. The genotype of each mouse was 
determined by polymerase chain reaction (PCR) with DNA isolated using the DNeasy 
Tissue Kit (Quiagen) with primers displayed in table 2.1.  Mice were fed a chow diet 
(5.5% fat by weight; 5001 Purina Laboratory Rodent Diet) ad libitum for 9 weeks 
beginning at 3 weeks of age and all studies were performed at 12 weeks of age.  
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Primer Sequence 
Cre GTGAAACAGCATTGCTGTCACTT 
MCK forward TAAGTCTGAACCCGGTCTGC 
+ Control Forward CAAATGTTGCTTGTCTGGTG 
+ Control Reverse GTCAGTCGAGTGCACAGTTT 
VEGF LOX Forward CCTGGCCCTCAAGTACACCTT 
VEGF LOX Reverse TCCGTACGACGCATTTCTAG 
  Table 2.1 – PCR primer sequences 5’ to 3’ to genotype mVEGF+/+ and mVEGF-/-        
mice 
 
Commercially available C57BL/6J mice male mice were ordered from Jackson 
Laboratory at 6 weeks of age and were either fed ad libitum a chow (5001 Laboratory 
Rodent Diet) or high fat (F3282 Bioserv) diet containing 5.5% or 60% calories as fat to 
metabolically stress the mice in Chapter IV and V. The cohorts of mice in Chapter IV 
were all studied at 19 weeks of age and were individual housed to protect mice from 
injury due to fighting. Mice in Chapter V were studied at 22 weeks of age. In all studies 
mice were weighed and handled weekly to observe any health issues and to acclimate 
mice to prevent stress from handling during the studies. 
 
Surgical Procedures 
Prior to the onset of any surgical procedure mice were anesthetized with 40-85 
mg/kg pentobarbital or with isoflurane. Surgical setup and processes were performed in 
an aseptic environment to prevent infection. Once anesthetized, mice were prepped by 
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removing hair around the surgical site. The shaved area was disinfected with alcohol 
followed by betadine scrub.  
An incision was first made 5 mm cephalic to the sternum and the left 
sternomastoid muscle was exposed. The sternomastoid muscle was reflected to reveal the 
left carotid artery. Once the artery has been located the connective tissue and vagus nerve 
were separated from the vessel. A silk suture was tied at the cephalic end and another 
loosely knotted on the caudal end of the carotid. The artery was clamped with a micro-
serrefine and cut just below the ligated end and the catheter was inserted until the tip 
reached the aortic arch. The ligatures were secured and catheter sampling confirmed. 
An incision was made 5 mm to the right of the midline and 2 mm caudal to the 
incision for the carotid catheter. The jugular vein was isolated and ligated at the cephalic 
end with a loose knot at the caudal end similar to the carotid catheter. The catheter for the 
jugular vein was inserted after a small incision and flushed to assure infusion. For the 
glucose tolerance tests the catheter was inserted directly into the stomach cavity in lieu of 
the jugular vein. 
A third incision was made between the shoulder blades of each mouse and a 14-
gauge needle was tunneled under the skin. The catheters (carotid and jugular or gastric) 
were threaded through the needle to tunnel out of the back of the mouse. The ventral 
incisions were closed with a nylon suture. The arterial catheter was clamped with micro-
serrefine at the incision site between the shoulder blades. The catheter was cut 1 cm 
above the clamp and connected to the MASA™ with a silk suture and repeated for the 
either the venous or gastric catheter. The dorsal incision was closed with nylon sutures. 
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Special attention was given to post-operative care to assure each mouse fully 
recovered within a 5-7 day timeline before performing each study by observing body 
weight, grooming behavior, and other signs of stress daily. This care was important to 
perform quality studies. Mice were immediately placed into clean cages, which sit on a 
heating pad. Animals were observed daily for any abnormal behavior cues and weighed 
daily.  
Surgical procedures are outlined in the Vanderbilt Mouse Metabolic Phenotyping 
website for their annual clamping course (www.mc.vanderbilt.edu/mmpc) (113).  
 
In Vivo Experiments 
Hyperinsulinemic-Euglycemic Clamp (insulin clamp) 
Mice were allowed to recover for five-seven days after surgical implantation of 
carotid artery and jugular vein catheters. Mice that did not weigh within 10% of the 
presurgical weight were excluded from any clamp studies. Mice were fasted for 5 h prior 
to the start of clamps to assure all mice were in the post-absorptive phase. The mice were 
placed in a 1 L plastic tub at the start of the fast (7:00am) and after an hour acclimation 
period mice were attached to a swivel from their catheter lines to allow free movement. 
The method employed by our laboratory differs from those performed by most other 
laboratories (114, 115) in that mice were not handled and were unstressed (15). Red 
blood cells were replaced to prevent a fall in hematocrit that would inevitably occur. 
Samples for basal arterial glucose specific activity were taken at t = -15 and -5 min and 
arterial insulin at t= -5 min. The clamp was initiated at t=0 min with a continuous insulin 
infusion (4mU·kg
-1
·min
-1
) that persisted for 155 min. Arterial glucose concentrations 
30 
 
were determined at 10 min intervals to provide feedback to adjust the rate of exogenous 
glucose (glucose infusion rate; GIR) as needed to clamp mice between 150-160 mg/dL. 
Steady state [3-
3
H]glucose kinetics were determined at 10 min intervals between t= 80-
120 min. The [3-
3
H]glucose infusion began at t= -90 min to allow for a priming dose (2 
µCi/min for 1.2 min, then  0.04 µCi/min) to reach a steady-state level and continued at 
0.12 µCi/min during the clamp period. Plasma insulin concentrations during the clamp 
were determined at t= 100 and 120 min. A 13 µCi injection of 2[
14
C]deoxyglucose 
(2[
14
C]2DG) was administered as an intravenous bolus at t=120 min. 2[
14
C]2DG was 
used to determine the glucose metabolic index (Rg), an indication of tissue specific 
glucose uptake. Blood samples were then collected at t= 2, 15, 25 and 35 min after the 
bolus to measure the disappearance of 2[
14
C]DG from the plasma. After the last sample 
of the insulin clamp, 50 µL yellow DYE-TRAK
®
 15µm microspheres were injected into 
the carotid artery to determine microsphere content in skeletal muscle and the left and 
right kidney. Clamp setups are depicted in Figures 2.1-2.3. 
 
Saline Clamp 
Saline infusion protocols were performed using the same design as the insulin 
clamp. However, saline was infused in lieu of insulin and glucose during the 155 min 
clamp period. This setup permitted the measurement of fasting muscle glucose uptake 
and served as a time control for the insulin clamp. 
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Glucose Tolerance Tests 
One week prior to glucose tolerance tests (GTT), mice had indwelling carotid 
artery and gastric catheters surgically implanted for sampling and glucose administration. 
Mice were studied in the postabsorptive state after a 5 h fast. Baseline arterial glucose 
and insulin measurements were obtained via the arterial catheter to avoid handling of 
mice. Mice were then administered 2g/kg body weight of glucose through the gastric 
catheter. The gastric catheter permitted the mice to absorb the glucose via physiological 
mechanisms and to avoid a stress response from intraperitoneal injection or gavage. 
Arterial glucose was measured at 5, 10, 15, 20, 30 45, 60, 90, and 120 min after glucose 
administration. Arterial insulin levels during the GTT were assessed at 10, 20, 30, 60, and 
120 min. 
 
Body Composition and Cardiac Function 
 Body composition was determined with a mq10 nuclear magnetic resonance 
analyzer (Bruker Optics) in 5 h fasted mice. Echocardiogram (Sonos 5500 system; 
Agilent) was used to assess cardiac function, and blood pressure was measured with a 
blood pressure transducer via a carotid arterial catheter with the assistance of the 
Cardiovascular Pathophysiology and Complications Core of the Vanderbilt Mouse 
Metabolic Phenotyping Center. 
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Ex Vivo Experiments 
Isolated Muscle Glucose Uptake 
Isolated soleus (mainly slow-twitch fibers) and extensor digitorum longus (mainly 
fast-twitch fibers) muscles were obtained from 5 h fasted, anesthetized mice to measure 
glucose uptake. After a 15 min basal incubation period, muscles were transferred to fresh 
media and incubated for 30 min in the absence or presence of insulin (10mU/mL). 
Following stimulation, 2-deoxy-D-glucose uptake was measured for 10 min in fresh 
media in the absence or presence of insulin, by adding cold 2-deoxy-D-glucose (1mM), 
2-[1,2-
3
H]deoxy-D-glucose (0.25Ci/mL), and D-[1-14C]mannitol (0.16Ci/mL). Muscles 
were then lysed and radioactivity in the supernatant was measured using liquid 
scintillation counting (116). 
 
Aortic Ring Reactivity 
Mouse aortas were excised after the clamp and placed directly in HEPES buffer 
(140 mM NaCl, 4.7 mM KCl, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 1.5 mM CaCl2, 10 
mM glucose, and 10 mM HEPES, pH 7.4). The aortas were equilibrated with 95% 
oxygen and 5% carbon dioxide at 37°C. The excised aortas were suspended in a muscle 
bath apparatus. Subcutaneous fat and adventitial tissues were removed after which the 
aorta was sectioned to create rings. The rings were progressively stretched to an optimal 
resting tension that produced a maximal response to contractile agents. Force 
measurements were obtained with a Radnoti Glass Technology force transducer 
interfaced with a Powerlab data acquisition and Chart Software (ADInstruments). 
33 
 
Contraction was first generated with 110 mM KCl to determine functional viability and 
the rings that did not contract were discarded. Functioning aortic rings were equilibrated 
in bicarbonate buffer for 30 min and then contraction was induced by phenylephrine (10
-6
 
M). Percent endothelial relaxation was measured from precontracted rings that were 
treated with carbachol (5 x 10
-7
 M). Quality of the intact endothelial layer was 
determined by whether carbachol induced vasoconstriction in lieu of dilation. Carbachol 
causes smooth muscle dependent constriction in the absence of functional endothelium. 
Sodium nitroprusside (10
-7
 M) was applied to determine smooth muscle specific 
relaxation. The percent relaxation was calculated by the change in stress compared with 
the maximal tension induced by phenylephrine (117, 118). Stress was determined by 
converting force measurements with the following equation:  
10
5
 N/m
2
 = force (g) x 0.0987/area 
where the area was equal to the wet weight in milligrams divided by the length divided 
by 1.055. 
 
Processing Plasma Samples 
Plasma Radioactivity 
Radioisotopes of glucose were infused during the insulin clamp protocol to 
measure steady-state plasma [3-
3
H]glucose and the disappearance of plasma 2[
14
C]DG  
after the venous injection. Plasma samples were treated with diluted 0.3 N barium 
hydroxide and 0.3 N zinc sulfate for deproteinization. Radioactivity of plasma [3-
3
H]glucose and of 2[
14
C]DG were assessed by liquid (Ultima Gold; Packard) scintillation 
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counting (Packard TRI-CARB 2900TR). Samples for the measurement of plasma [3-
3
H]glucose underwent a drying procedure to remove all 
3
H2O from the plasma as a result 
of glycolysis of the radioactive glucose tracer.  
 
Plasma Enzyme-Linked Immunosorbent Assay of Insulin 
Plasma insulin was collected during all the insulin and saline clamps performed at 
indicated times from each protocol. Ten µL of plasma, standard, and control were 
transferred into a 96-well plate as instructed by the manufacturer (80-INSMS-E01; 
Alpco). The supplied plate has mouse monoclonal antibodies specific for insulin 
immobilized to each well. A conjugate was added that includes horseradish peroxidase 
enzyme labeled monoclonal antibody resulting in the insulin from the plasma samples to 
be sandwiched between the immobilized and conjugate antibodies. Unbound conjugate 
was washed and TMB substrate added for incubation. The final step was the addition of a 
stop solution and the optical density was measured at 450 nm with a reference at 620 nm. 
The intensity of the optical density read at 450 nm was proportional to the amount of 
insulin from the plasma sample.  
 
Plasma Non-Esterified Fatty Acid 
Non-esterified free fatty acids (NEFA) were assessed spectrometrically by an 
enzymatic calorimetric assay (NEFA C Kit; Wako Chemicals). Basal FFAs were an 
average of samples taken at t= -15 and -5 min and the FFA levels during the insulin 
clamp were the average at t= 80 and 120 min. Whole blood was collected in EDTA tubes 
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and the plasma transferred to dried THL. The NEFA assay is based on the following 
chemical reactions: 
 
NEFA + ATP + CoA-SH                   Acyl-CoA + AMP + PPi 
Acyl-CoA + O2                  2,3-trans-Enoyl-CoA + H2O2   
2 H2O2 + 4-Aminophenazone + MEHA                   Quinoneimine-color + 4H2O   
 
The intensity of the red pigment was proportional to the NEFA concentration of the 
plasma sample. The ascorbic acid was removed by ascorbate oxidase and the absorbance 
of the 96-well plate read at 550 nm.  
  
Processing Tissue Samples 
Tissue Radioactivity 
Tissue samples were weighed to approximately 30 mg and the appropriate amount 
and style of Bullet Blender™ beads were added for tissue homogenization. The combined 
tissue and beads were homogenized using the Bullet Blender™ in 750 µL 0.5% 
perchloric acid according to the manufacturer’s instructions. Samples were then 
centrifuged at 13,000 rpm for 10 min. To measure the radioactivity of 2[
14
C]DG-6-
phosphate and 2[
14
C]DG, 125 µL of the supernatants were transferred directly into a 
scintillation vial for counting. Another 125 µL aliquot from each sample was 
deproteinized with 0.3 N barium hydroxide and 0.3 N zinc sulfate. The supernatant, 250 
µL, from this mixture was transferred to scintillation vials for the counting of 2[
14
C]DG. 
ACS 
ACOD 
POD 
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To determine the quantity of tissue 2[
14
C]DG-6-phosphate, the amount of 2[
14
C]DG was 
subtracted from the total quantity of the tracer within the tissue.  
 
Hepatic Glycogen Content 
Liver glycogen content was determined after the insulin clamp and a time control 
experiment during which saline was infused as previously reported by Chan and Exton 
(119). The latter experiment was useful in obtaining a measure of fasting liver glycogen 
for comparison to insulin clamp glycogen concentrations. Livers were homogenized in 
10% (w/v) in 0.03 N HCl. The liver suspensions were boiled for 10 min and 200 µL of 
each sample was transferred to the corresponding chromatography paper and briefly 
dried. As a standard and control, 200 µL oyster glycogen (5 mg/mL) and 0.03 N HCl 
were transferred to paper strips. The paper strips were washed 3x for 40 min per wash in 
a 70% ethanol solution using a stir plate. After the last wash, the ethanol was poured off 
and the strips were briefly rinsed with acetone. The paper strips were dried overnight in a 
ventilation hood. The dried strips were transferred into a 5 mL solution of 
aminoglucosidase containing 20 mg aminoglucosidase, 100 mL 0.2 M NaOAc buffer, 
and 400 mL distilled water. The tubes were placed in a shaking water bath at 37°C for 3 
h. Glucose concentration was then measured enzymatically in a 96 well plate at 340 nm. 
The following reaction was used: 
 
Glucose + ATP                         Glucose-6-phosphate + ADP 
 
Glucose-6-phosphate + ADP                          6-phospho-D-gluconolactone + NADPH 
Hexokinase 
G6PDH 
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Standard glucose concentrations were used to measure known equivalent NADPH, which 
was used to generate a standard curve for the measurement of the absorbance for the 
glucose concentrations of each sample.   
 
Glycogen Synthase Activity 
Liver tissues were homogenized in buffer containing 50 mM Tris buffer, 100 mM 
sodium fluoride, 10 mM EDTA, 0.5% glycogen, and 5 mM dithiothreitol at pH 6.8. 
Twenty-five µL of homogenates were added to 50 µL of a solution that contains 50 mM 
Tris buffer pH 7.5, 5 mM EDTA, 1% glycogen; 1.5 mM UDPG and UDPG labeled with 
14
C in glucose. The medium for the synthase a activity contains 15 mM in Na2SO4 and 
the medium for total synthase (a + b) had the sulfate replaced with 3 mM glucose-6-
phosphate. The samples were the incubated at 37°C for 0, 15, and 30 min and glycogen 
was analyzed as described in the previous section. Synthase activity in the presence of 
glucose-6-phosphate reflects the maximal enzyme activity, while activity in the absence 
of glucose-6-phosphate reflects the active form of glycogen synthase as previously 
described (120). 
 
Microsphere Tissue Content 
Gastrocnemius and both kidneys were collected in 15 mL polypropylene tubes 
and digested overnight in 6 mL of 1 M KOH in a temperature controlled oven set to 
60°C. After the overnight incubation, the tubes were vortexed to completely homogenize 
each sample and incubated again at 60°C for 1 h. Each sample was filled to 14 mL total 
volume with 50°C distilled water. Tubes were centrifuged for 15 min at 1,500 g and the 
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supernatant aspirated. The pellets were resuspended in 12 mL 10% Triton X-100 and 
sonicated prior to repeating the centrifugation step for 5 min. The pellets were 
resuspended in 12 mL acidified ethanol and centrifuged. The pellets were resuspended in 
12 mL ethanol. After the centrifugation step the samples were left to dry overnight in a 
ventilation hood. The fluorescent dye in the microspheres was eluted with 150 µL of 
N,N-dimethylformide and absorbance measured from 100 µL of each sample. 
Absorbance was measured at 450 nm (yellow) and 670 nm (blue) in 96-well 
polypropylene plates. Blue microspheres were added after the overnight digestion to 
monitor assay recovery to permit correction of microspheres lost during processing.  The 
number of microspheres per muscle was normalized to weight of each tissue processed 
and the number of microspheres was based on a known standard curve from the 
manufacturer. 
 
Immunoprecipitation and Immunoblotting  
Cardiac, liver, and gastrocnemius samples were homogenized in buffer containing 
50 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 1 
mM DTT, 1 mM PMSF, 5 µg/mL protease inhibitor, 50 mM NaF, and 5 mM sodium 
pyrophosphate. Samples were then centrifuged at 13,000 rpm for 20 min at 4°C and 
supernatants collected. All samples were diluted 1:20 to determine protein concentrations 
using the Bradford protein assay. Protein was assessed using 96-well plates at a 
wavelength of 595 nm and albumin protein standards were used to generate a standard 
curve to calculate protein concentrations. 30 µg of the supernatant was loaded onto 4-
12% SDS-PAGE gel and then transferred to a PVDF membrane. All membranes were 
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blocked in commercially available Odyssey Blocking Buffer or 5% milk for 1 h at room 
temperature. Membranes were incubated overnight at 4°C with primary antibodies for 
phosphorylated Akt (Ser 473), total Akt (Cell Signal), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Abcam), phosphorylated SMAD2 (Ser 465/467; Cell Signal) 
and total SMAD2 (cell signal). Membranes were washed then incubated with secondary 
antibodies for α-mouse or α-rabbit IRDye™ 700/800 to be visualized using the Odyssey 
system (Li-Cor).  Enhanced chemiluminescence was performed with horseradish 
peroxidase conjugated α-rabbit secondary antibody for phospho-SMAD2 visualization. 
GAPDH was used as the loading control for each blot.  
Immunoprecipitation was performed using 500 µg of the gastrocnemius protein 
supernatant and incubated with 3 µg of IRS-1 antibody (Santa Cruz Biotechnology) 
overnight at 4° C. Then, 20 µl of protein A/G PLUS-Agarose (Santa Cruz Biotechnology) 
was added and incubated overnight at 4° C. The mixture was centrifuged at 1,000 g and 
the supernatant removed. The beads were washed 4 times with cold PBS and 
centrifugation step repeated. Beads were resuspended in 30 µl NuPAGE LDS loading 
buffer and heated at 80° C for 5 min. Immunoblots were incubated with primary 
antibodies for phospho-IRS-1 (Tyr612; Invitrogen) and the p85 subunit of 
phosphoinositide (PI) 3-kinase (Millipore). For all blots, secondary antibodies were 
incubated at room temperature for 1 h and visualization and quantifications were 
performed using the Odyssey imaging system and ImageJ software. 
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Tissue and Plasma VEGF Protein 
The gastrocnemius and cardiac muscles were homogenized in a lysis buffer 
containing 50 mM Tris-HCl (pH 7.4), 150 mM Na Cl, 0.5% Triton X-100, and protease 
inhibitors (Halt™ Protease Inhibitor Cocktail; Fisher Scientific) as previously described 
(76). Tissue homogenates were centrifuged at 4°C, 7200 g, for 10 min and protein 
content measured. The plasma and tissue VEGF concentrations were assayed by the 
manufacturer’s specifications (VEGF ELISA Kit, Mouse No. QIA52; Calbiochem), 
which detects VEGF120 and VEGF164 isoforms. 
 
Immunohistochemistry Analysis of Capillary Density and Extracellular Matrix 
Composition 
CD31, collagen III, and collagen IV proteins were assessed by 
immunohistochemistry in paraffin-embedded cardiac, skeletal, and liver sections.  Five 
µm sections were incubated for 60 min with anti-CD31 (BD Biosciences), collagen III 
(CosmoBio), and collagen IV (Abcam) primary antibodies. Slides were counterstainted 
with Mayer hematoxylin. The EnVision+HRP/DAB System (DakoCytomation) was used 
to produce localized, visible staining with assistance from the Vanderbilt University 
Immunohistochemistry Core. Images were obtained using a Q-Imaging Micropublisher 
camera mounted on an Olympus microscope. Muscle capillary density was determined by 
counting CD31 positive structures. Collagen protein content was quantified by measuring 
integrated intensity of staining. Quantification was carried out by ImageJ software. 
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Transmission Electron Microscopy of Skeletal Muscle Capillaries 
Mice were anesthetized and chest cavity opened for insertion of a catheter into the 
left ventricle. With gentle pressure, cacodylate buffer (0.1 M) was perfused through the 
mouse vascular system to rinse erythrocytes from the circulation (~50 mL). Once flow 
was confirmed by observing rigidity in organs such as the kidney, the liver was nicked to 
relieve pressure to prevent rupture of blood vessels. Blood and buffer leaked from the 
liver until the solution was a pale pink, which indicates the mouse had been sufficiently 
rinsed with the buffer. At this time point the buffer was replaced with 2.5% 
glutaraldehyde in cacodylate buffer (~75 mL) to allow for muscle fixation. Contractino of 
the arms and legs indicated that the muscle had been appropriately fixed. The left red 
gastrocnemius was excised from the mouse and cut into pieces (less than 1 mm on two 
sides) and placed in a vial of fresh fixative. The tissues were allowed to rest for 1 h and 
then placed into a 4°C refrigerator until further processing.  
Once samples were fixed the Vanderbilt University Cell Imaging Shared 
Resource Core further processed the samples for transmission electron microscopy. The 
tissues were dehydrated through a series of diluted ethanol up to 100% and embedded in 
Spur resin. Thick sections (0.5 µm) were cut and stained with toluidine blue for light 
microscopic examination to select regions of interest. An area of 500 µm x 500 µm was 
selected from each sample with equivalent cross sections to permit equivalent imaging 
across all samples. Thin sections were cut (80 nm) from the regions of interest and 
examined using a Philips/FEI T-12 transmission electron microscope operated at 80 kilo-
electron volts. Capillary structures were identified with a random and unbiased technique 
that allows the location of a structure at low magnification to be marked by observing the 
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section grid without detecting ultrastructures. Images were acquired at 67,000 
magnification for quantification of caveolae area per endothelial cell area.  
ImageJ software was used to quantify the caveolae area per single endothelial cell 
capillary within skeletal muscle. ImageJ generates a random grid box that overlays the 
micrograph and by counting the number of points within the caveolae / number of points 
within the endothelial cell permits calculation of area of caveolae per each endothelial 
cell. Two ImageJ plugins were downloaded for this analysis: Grid and Multipurpose Grid 
(121-123).  
  
Reverse Transcription (RT) Polymerase Chain Reaction (PCR) 
 Total RNA was isolated from liver tissue using the RNeasy Mini Kit (Qiagen). 
Total RNA (1 mg) was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-
Rad). RNA concentration and quality were measured at absorbance wavelength 260 and 
280 nm. Real-time PCR was then performed using TaqMan® Universal PCR Master Mix 
(Applied Biosystems) on the CFX Real Time PCR Instrument (Bio-Rad). Expression of 
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) were 
measured. Data were normalized with either control gene, ribosomal protein 18S. 
Primer Assay ID 
PEPCK Mm01247058_m1 
G6Pase Mm00839363_m1 
18S Mm03928990_g1 
  Table 2.2 – RT- PCR assay ID numbers purchased from Life Technologies  
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Gelatin Zymography 
The activation of MMP-2 and -9 were determined using the gelatin zymograph 
technique. Gastrocnemius muscles were homogenized in buffer containing 0.5% Triton 
X-100, 100 mM EDTA, and 10 µL/mL protease inhibitor (pH 7.5). Homogenates were 
centrifuged at 13,000 rpm for 20 min. Supernatants were incubated at 4°C for 2 h with 40 
µL of gelatin-Sepharose (Pharmacia) to concentrate the protein and washed 3x with 
equilibration buffer containing 200 mM NaCl. The gelatin-Sepharose beads were 
resuspended in 20 µL of 4x nonreducing SDS-sample buffer and loaded on 10% 
zymogram gels (Invitrogen). The gel was incubated at 37°C in a buffer containing 50 
mM Tris-HCl, 0.2 M NaCl, 20 mM CaCl2, pH 7.4 for 12 h. Gels were stained with 
Coomassie brilliant blue R-250 0.5% (w/v) in 45% methanol (v/v), 10% ascetic acid 
(v/v), and destained in the solution without Coomassie. Gels were developed according to 
manufacturer’s instructions and quantified using ImageJ software.  
 
Calculations 
Glucose Flux Analyses  
Glucose production (Ra) and disappearance (Rd) were calculated using Steele 
non-steady state equations (124). The endogenous Ra was determined by subtracting the 
GIR rate during the clamp from the total Ra. When the tracer infusion was in steady-
state, which should correspond to minutes 80-120 of the clamp, the equation for Ra 
simplifies: 
 
44 
 
   
 
  
 
where I is the tracer infusion rate and SA is the specific activity of the tracee (dpm/mg). 
To measure the index for tissue glucose uptake (Rg), the following equation was applied 
(86): 
    
 [   ]         
    [   ]        
 [                ] 
where  [   ]          is the [   ]    in the muscle (dpm/g),     [   ]         is the 
area under the curve for the disappearance of plasma  [   ]   (dpm·min·mL-1), and 
[                ] is the average blood glucose (mmol/L) from t= 122-155 min of the 
clamp.  
 
Western Blot and RT-PCR Quantification  
Western blot protein intensities were determined by ImageJ or Odyssey software 
analysis image intensity and all proteins were normalized to GAPDH. Real-time RT-PCR 
gene expression levels were analyzed using the 2
-ΔΔCt
 method (125) and presented as 
relative expression. GAPDH or 18S were used to standardize for gene loading of each 
sample.  
 
Statistical Analysis  
Student t-test or two-way ANOVA, followed by Tukey’s post hoc tests when 
appropriate, were used to determine statistical significance. Data are expressed as mean ± 
SE. The significance level was P ≤ 0.05. 
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Figure 2.1 – Experimental setup for the hyperinsulinemic-
euglycemic clamp 
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Figure 2.2 – Experimental setup for the saline clamp 
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Figure 2.3 – Experimental setup for the hyperinsulinemic-
euglycemic clamp with acute relaxin infusion 
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Chapter III 
 
LOSS OF VASCULAR FUNCTION: CAPILLARY RAREFACTION IS 
SIGNIFICANT TO THE PATHOGENESIS OF SKELETAL MUSCLE INSULIN 
RESISTANCE 
 
Aims  
The goal of Chapter III was to determine whether capillary rarefaction is a cause 
or a consequence of muscle insulin resistance.  The microvascular adaptations that are 
present in insulin resistance have been well established. However, previous studies rely 
on correlative data that suggests a causative relationship between capillary rarefaction 
and skeletal muscle insulin resistance. The current Aim investigated whether a decrease 
in the number of capillaries that perfuse skeletal muscle directly impairs insulin-
stimulated MGU in otherwise healthy mice. To address this Aim, mice with muscle-
specific genetic deletion of vascular endothelial growth factor-A were utilized to induce 
muscle capillary rarefaction in low fat chow-fed mice. This genetic mouse model permits 
the investigation into the specific consequence of reducing capillary number to insulin-
stimulated MGU. The hypothesis tested within Chapter III was that capillary rarefaction 
specifically impairs insulin-stimulated MGU by increasing the resistance to the delivery 
component of MGU.  
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Introduction 
 
Insulin resistance is closely associated with cardiovascular disease and together 
are central to the metabolic syndrome (126). Skeletal muscle contributes ~80% of 
insulin-mediated glucose disposal, thus impairments in insulin-stimulated MGU are 
critical to the pathogenesis of insulin resistance.  Pharmacologically limiting glucose and 
insulin delivery to the muscle impairs insulin-stimulated MGU (59). Moreover, there is a 
correlation between reduced blood flow to the muscle and insulin resistance (17, 18, 31, 
47). Recent studies have linked diet-induced extramyocellular adaptations to insulin 
resistance in rodent models (53, 87, 127) and humans (111). The number of capillaries 
perfusing the muscle is positively related to peripheral insulin action - independent of 
age, body composition, energy expenditure, and lipid status (128). The important 
question that remains to be answered is whether the reduction in capillaries is a cause or 
consequence of muscle insulin resistance. 
Insulin recruits unperfused capillaries which enhances nutrient blood flow to 
metabolically active muscle. The augmented microvascular blood volume precedes 
insulin-stimulated MGU (45). Studies estimate that 40% of insulin-stimulated MGU 
results from increased muscle perfusion and this hemodynamic response is absent in 
patients with type 2 diabetes (36, 37, 47, 48, 50, 57, 59). Muscle capillarity is an 
important predictor of insulin-mediated glucose disposal and, accordingly, insulin 
resistant humans and rodents exhibit capillary rarefaction (51, 53-55, 80). 
Pharmacological agents that target the vasculature to increase tissue perfusion also 
improve skeletal muscle insulin resistance and augment muscle microvascular density 
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(53, 86, 87). This affirms the importance of restoring skeletal muscle perfusion in 
ameliorating insulin resistance (53, 86, 87, 129). 
The vascular endothelial growth factor (VEGF) family of proteins regulate 
vasculogenesis, angiogenesis, and lymphanogenesis (130). In particular, VEGF-A 
stimulates the formation of new vascular networks by recruiting and differentiating 
endothelial progenitor cells in addition to inducing endothelial cell proliferation and 
migration (130). Insulin resistant states are characterized by impaired VEGF-A action in 
the vascular beds of cardiac and skeletal muscle triggering capillary regression (51, 79, 
82, 131). Cardiac and skeletal myocellular VEGF-A production regulates capillarity by 
paracrine signaling to the endothelium (75, 76). Capillary density correlates with the 
severity of insulin resistance in obesity; however, the specific effect of capillary 
rarefaction to the pathogenesis of skeletal and cardiac muscle insulin resistance has not 
been elucidated (53, 54, 127, 128).  
The experiments described herein test the hypothesis that skeletal and cardiac 
muscle capillary rarefaction, in lean, otherwise healthy mice impairs muscle insulin 
action. Genetic deletion of skeletal and cardiac muscle VEGF-A (referred to as VEGF in 
subsequent sections) was used to selectively reduce muscle capillarity in lean mice to 
determine the specific consequence of capillary rarefaction on insulin-stimulated MGU. 
 
Experimental Design 
Mice with genetic deletion of skeletal and cardiac muscle VEGF-A (mVEGF
-/-
) 
and wild-type (mVEGF
+/+
) were studied as a genetic model of capillary rarefaction. This 
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model permits the investigation of the direct effects of microvascular density, 
independent of another known insulin resistant insult (e.g. diet), in the pathogenesis of 
muscle insulin resistance. Mice were fed a low fat chow diet for 9 weeks and glucose 
regulatory effects were studied at 12 weeks of age. To determine the effects of capillary 
rarefaction on glucose kinetics mice either underwent an insulin clamp (Figure 3.1), 
saline clamp (Figure 3.2), or glucose tolerance test (Figure 3.3). Cardiac function was 
assessed by echocardiography. See Chapter II for detailed methods.  
 
Results 
Adaptations to genetic ablation of skeletal and cardiac muscle VEGF  
There were no differences in total body, fat, or lean masses at 12 weeks of age 
(Table 3.1). VEGF levels in cardiac and skeletal muscle of mVEGF
-/-
 mice were 
undetectable, compared to ~30 pg/mg protein in cardiac and skeletal muscle of 
mVEGF
+/+
 littermates (Figure 3.4A; p≤0.001). The reduction in VEGF protein 
corresponded to 60% and 50% decreases in capillary density in skeletal and cardiac 
muscle respectively (Table 3.1; p≤0.05). Plasma VEGF levels were similar in both 
groups (Figure 3.4B). Cardiac output was equal between genotypes (Table 3.1) as heart 
rate and stroke volume, calculated from the echocardiography, did not differ (data not 
shown). Furthermore, mean arterial pressure was similar between genotypes (Table 3.1). 
Left ventricular (LV) volume and LV mass were significantly increased in the mVEGF
-/-
 
mice but, ejection fraction and fractional shortening were 2 and 2.5-fold lower (Table 3.1; 
p≤0.05).   
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mVEGF
-/-
 mice have impaired insulin-stimulated glucose disposal and augmented 
fasting hepatic glucose turnover  
Basal (5 h fasting) and insulin clamp arterial glucose and insulin did not differ 
between genotypes (Table 3.2). The basal circulating FFA concentrations and the 
suppression of FFA by insulin were similar between genotypes (Table 3.2). The steady-
state GIRs were equal (Figure 3.5B). Fasting endogenous glucose production (EndoRa) 
and glucose disappearance (Rd) were 1.6-fold greater in mVEGF
-/-
 mice (Figure 3.5C and 
D; p≤0.05). The relative gene expression for phosphoenolpyruvate carboxykinase 
(PEPCK; Figure 3.6D) was not different between genotypes, however, glucose-6-
phosphatase (G6Pase; Figure 3.6D; p≤0.05) was higher in mVEGF-/- mice and may have 
contributed to the augmented fasting EndoRa. The suppression of EndoRa and the 
absolute whole-body Rd during insulin stimulation were similar between groups (Figure 
3.5C and D). Notably, the increase in insulin-stimulated glucose disposal was blunted by 
56±16% in the mVEGF
-/-
 mice suggesting an impairment in peripheral insulin action 
(Figure 3.5E; p≤0.05). The results from the GTTs (Figure 3.6A) indicated that mVEGF-/- 
mice were less glucose tolerant than their wild-type littermates. The area under the curve 
for the first 30 min (Figure 3.6C; p≤0.05) of the GTT was greater in the mVEGF-/- mice 
and the insulin response did not differ except for the 60 min time point (Figure 3.6B). 
Consistent with the impairment in insulin-stimulated whole-body Rd, insulin-
stimulated Rg in skeletal and cardiac muscle in mVEGF
-/-
 mice was also abated compared 
to mVEGF
+/+ 
littermates (Figure 3.7A and B; p≤0.05). Insulin-stimulated Rg is the 
difference between the Rg during the insulin clamp and an average Rg from the saline-
infused cohort of mice. The data obtained from these saline-infused time controls permit 
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the quantification of the specific effect of insulin on Rg. Furthermore, in vivo insulin 
signaling in skeletal muscle was attenuated during the insulin clamp evident by a 
decrease in the association of the p85 subunit of PI 3-kinase with phospho-IRS-1 (Figure 
3.8B; p≤0.05). Interestingly, downstream Akt activation, which is central to multiple 
signaling pathways in muscle, was unaffected during the insulin clamp (Figure 3.8D).  
 
Muscle Insulin action is decreased in mVEGF
-/-
 mice in vivo, but not in vitro 
Glucose uptake was analyzed on isolated muscle, thus removing the 
extramyocellular barriers to MGU. Isolated MGU was determined in the soleus (slow-
twitch) and extensor digitorum longus (EDL) (fast-twitch) muscles. The basal and 
insulin-stimulated glucose uptake in isolated skeletal muscles were equal between 
genotypes (Figure 3.9) suggesting no direct impairment of insulin action at the myocyte. 
The data in isolated muscle contrasts with the muscle glucose uptake and insulin 
signaling data from the insulin clamp, which were diminished as described above. These 
data indicate insulin action was impaired by muscle VEGF deletion in the whole 
organism where extramyocellular factors are present, but not in isolated muscle where 
they are not. This strongly suggests that muscle VEGF deletion results in resistance to 
insulin because of an impaired capacity to deliver insulin to the sarcolemma. 
 
Liver glycogen content was greater in mVEGF
-/-
 mice after the insulin clamp 
Whole-body Rd was elevated in the basal state of mVEGF
-/-
 mice and equal during 
the insulin clamp. Liver glycogen content was assessed after the insulin clamp to test the 
possibility that liver glucose uptake was compensating for the impaired insulin-stimulated 
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MGU. Consistent with this possibility mVEGF
-/-
 mice had a ~two-fold increase in liver 
glycogen concentrations compared to mVEGF
+/+ 
littermates (Table 3.2; p≤0.05). During 
the time control experiment, where saline was infused in lieu of insulin, fasting (7.5 h) 
liver glycogen levels (Table 3.2) were minimal and there was no significant difference 
between genotypes. The greater hepatic glycogen concentration in the mVEGF
-/-
 mice 
was independent of changes in phosphorylation of Akt in the liver (Figure 3.8F) during 
the insulin clamp. Hepatic glycogen synthase activity was assessed after the insulin 
clamp. mVEGF
-/-
 mice tended to have greater glycogen synthase activity (Table 3.2; p = 
0.08) which likely contributes to the greater liver glycogen content after the insulin 
clamp.  Thus, indirect adaptations at the liver may counterbalance the diminished insulin-
stimulated MGU and explain the similar total glucose utilization between the two 
genotypes during insulin stimulation (Figure 3.5B). 
 
Discussion 
These studies demonstrate that capillary rarefaction impairs muscle insulin action 
in vivo. Our data support the paradigm that capillary regression contributes to the 
pathogenesis of skeletal muscle insulin resistance. Diabetic states are characterized by 
muscle capillary regression which results from impaired VEGF action (75, 80). Here we 
show that local VEGF deletion is sufficient to cause muscle insulin resistance due to 
diminished muscle capillary density. Although the decrease in muscle capillaries is 
substantive it is also possible that an alteration in the vessel wall that affects permeability 
to insulin occurs. Previous studies have shown muscle capillarity strongly correlates with 
insulin-sensitivity (54, 55). Furthermore, serveral therapeutic treatments that reverse 
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muscle insulin resistance in mice augment capillary density (53, 87). Our data illustrates 
that attenuating capillarity specifically in muscle blunts insulin-stimulated Rd due to 
diminished muscle Rg, without directly affecting myocellular insulin action. Additionally, 
mVEGF
-/- 
mice were less glucose tolerant than their wild-type littermates despite similar 
insulin responses to a glucose load. These data emphasize the importance of increased 
muscle blood volume and capillary surface area for the delivery of insulin and glucose to 
skeletal muscle during hyperinsulinemia (37, 45, 59).  
The reduced insulin-stimulated MGU in mVEGF
-/-
 mice was not attributable to 
impaired insulin action directly at the myocyte; however, in vivo insulin signaling during 
hyperinsulinemia was blunted in mVEGF
-/- 
mice suggesting a defect in insulin delivery. 
There was no difference in ex vivo insulin-mediated glucose uptake in isolated muscles. 
Measuring glucose uptake in isolated muscle removes the vascular delivery component of 
MGU eliminating the difference between genotypes evident during the insulin clamp. 
Skeletal muscle does not express VEGF receptors indicating the decrease in muscle 
VEGF does not have direct effects at the myocyte (132). The association of the p85 
subunit of PI 3-kinase with phospho-IRS-1 during the insulin clamp was attenuated in 
mVEGF
-/- 
mice, though skeletal muscle Akt activation was preserved. Kim et al. 
demonstrated that insulin stimulated phosphorylation of Akt in diabetic muscle was 
normal and the primary deficiency in insulin signaling was attributed to a decrease in PI 
3-kinase association with IRS-1 (133). Our data are consistent with studies that showed 
the critical role of glucose and insulin delivery to insulin-stimulated MGU (17, 18, 27, 
36, 86). Moreover, in genetic- and diet-induced models of muscle insulin resistance the 
physiological actions of insulin to increase muscle microvascular recruitment and nutrient 
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blood flow are impaired resulting in an abatement in insulin and glucose delivery to the 
myocyte (18, 35, 47, 48, 134). The present data demonstrate that the attenuation in 
muscle capillary density associated with insulin resistance, in the absence of other 
primary defects, is capable of seriously diminishing insulin-stimulated MGU due to 
decreases in insulin and, likely, glucose delivery to the myocyte. It is also possible that 
other nutritional or endocrine factors that are deficient with poor muscle perfusion are 
necessary for the full response to insulin in vivo. These studies clearly demonstrate that a 
loss in muscle capillaries causes a marked impairment in muscle insulin action, thus, 
supporting the paradigm that capillary rarefaction in insulin resistant human skeletal 
muscle is not simply a consequence of the disease but central to the pathogenesis of 
muscle insulin resistance. 
At rest ~30% of capillaries are required to maintain the demand for skeletal 
muscle perfusion (135, 136). As a result of the low number of capillaries necessary to 
maintain nutrient blood flow, there was no defect in fasting MGU in mVEGF
-/- 
mice (data 
not shown). Physiological hyperinsulinemia recruits unperfused capillaries doubling the 
microvascular blood volume in the muscle (35, 137). The augmented insulin and glucose 
delivery to the muscle interstitium during hyperinsulinemia is dependent on the increased 
surface area for substrate exchange induced by insulin-mediated capillary recruitment 
(27, 35, 137). The ~60% attenuation in skeletal muscle capillary density in mVEGF
-/- 
mice resulted in an impairment in glucose uptake during steady-state hyperinsulinemia. 
This effect is similar to the decrease in capillary recruitment that prevents an increase in 
muscle blood volume and impairs muscle insulin action in obese, type 2 diabetic 
individuals (35).  
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In our model of muscle specific VEGF deletion, cre-recombinase is under the 
MCK promoter which is not expressed until fetal day 16 and then is upregulated post-
birth (138). This time course of VEGF ablation limits developmental abnormalities. 
VEGF expression is critical for embryonic development and the loss of a single VEGF 
allele in the whole organism causes embryonic lethality with developmental 
abnormalities evident by day 9.5 of gestation (71, 72). Furthermore, endothelial-specific 
deletion of VEGF results in endothelial apoptosis and sudden death in 55% of mutant 
mice by 25 weeks of age which indicates the importance of autocrine VEGF signaling in 
the maintenance of endothelial integrity in the adult animal (78). Olfert et al. showed in 
muscle-specific VEGF deficient mice that the attenuation in skeletal muscle capillary 
density occurs as early as at 1 month of age (76). The myocellular paracrine signaling of 
VEGF is essential for the spatial branching of the capillary network and is necessary for 
muscle capillary architectural organization (75, 77, 139). The capillaries present in 
mVEGF
-/-
 mice are likely a combination of refractory capillaries, VEGF independent 
capillaries, and vessels present prior to MCK expression that are maintained by autocrine 
endothelial VEGF signaling. 
Diabetic states are characterized by cardiac muscle capillary regression and 
impaired VEGF action (82, 131). Severe hyperglycemia downregulates VEGF 
expression, which is seminal in the pathology of diabetic cardiomyopathy (81). 
Endothelial cells are particularly sensitive to changes in plasma glucose because they are 
very permeable to glucose. VEGF ablation in our model resulted in a 50% decrease in 
cardiac capillary density. Notably, compensatory mechanisms kept cardiac output 
normal. The conserved cardiac output is a mathematical consequence of the decreased 
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ejection fraction coupled with the increase in left ventricular diastolic volume. The 
potential relationship of this to the underlying vascular pathology must be speculative at 
this point. The thinner but larger ventricular cavity might entail less transmural resistance 
to flow, allowing better capillary perfusion pressure through an attenuated vascular 
network. Alternatively, the larger endocardial surface area might allow some direct 
supply of oxygen and nutrients to the immediately adjacent myocardium, a mechanism 
important in the right ventricle, but potentially significant for the left ventricle in 
mVEGF
-/-
 mice. While the dilation in our model is common to many cardiomyopathic 
conditions, the preservation of cardiac output may be a consequence of this specific 
etiology. 
Basal glucose flux was elevated in mVEGF
-/-
 mice compared to mVEGF
+/+ 
littermates. Glucose homeostasis was maintained, despite the elevated glucose fluxes. 
mVEGF
-/- 
mice had greater liver glycogen deposition after the insulin clamp; however, 
there was no significant difference in fasting hepatic glycogen between the two 
genotypes. The greater liver glycogen in mVEGF
-/- 
mice may offset the reduction in 
insulin-stimulated muscle Rg, explaining the equal GIRs and absolute whole-body Rd 
during the insulin clamp. The augmented liver glycogen after the insulin clamp was 
independent of the phosphorylation status of Akt in the liver. However, glycogen 
synthase activity tended to be augmented in mVEGF
-/-
 mice. The elevated activity of 
glycogen synthase likely contributes to the higher hepatic glycogen concentrations in 
mVEGF
-/-
 mice after the insulin clamp. The presence of G6Pase in the liver obviates the 
use of isotopic 2-deoxyglucose to measure Rg in the liver, thus, no precise measurement 
of hepatic glucose uptake can be determined with the insulin clamp protocol performed in 
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the current studies.  Moreover, the increased basal glucose turnover suggests accelerated 
hepatic cycling of glucose independent of hepatic insulin action (140). However, this is 
unlikely with utilizing [3-
3
H]glucose. The increased fasting EndoRa may be due to the 
greater G6Pase expression in the liver of mVEGF
-/-
 mice.  The mechanism behind the 
hepatic adaptation is unclear. However, it is notable that untreated insulin resistant 
humans also have accelerated glucose production. 
The compensatory mechanisms in the mVEGF
-/- 
mice cannot be attributed to 
changes in circulating VEGF levels. Thus, the deletion of all VEGF-A variants in muscle 
is not likely to have direct physiological effects on other tissues. The compensation 
present in the liver is expected to be a consequence of the impaired insulin-stimulated 
MGU or perhaps inflammation secondary to heart or skeletal muscle hypoxia resulting 
from poor perfusion.   
These data show for the first time that a reduction in capillary density is sufficient 
to induce muscle insulin resistance in lean mice.  The present investigation is consistent 
with human data that exhibit a strong relationship between muscle capillary density and 
insulin-mediated peripheral glucose disposal (51, 52, 55). The results further elucidate the 
significance of the extramyocellular adaptations present in insulin resistant states, thus, 
highlighting the importance for novel therapeutic approaches to target the vascular bed of 
insulin sensitive tissues in the treatment of insulin resistance and type 2 diabetes.  
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Figure 3.1 – Protocol for the hyperinsulinemic-euglycemic clamps 
performed in Chapter III. Experiments were performed 7 days after surgical 
implantation of carotid artery and jugular vein catheters. Mice were fasted 
for 5 h prior to the onset of the clamp. Primed-continuous infusion of [3-
3
H]glucose began at t= -90 min. At t= 0 min insulin was elevated to 
postprandial levels. Basal blood draws occurred at t= -15 and -5 min and 
blood glucose was measured at 10 min intervals starting at t= 0 min. 
Variable glucose was infused to maintain euglycemia at ~150 mg/dL and 
red blood cell replacement maintained hematocrit during the study period. 
2[
14
C]glucose was injected intravenously at t= 120 min to measure tissue 
specific glucose uptake.  
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Figure 3.2 – Protocol for the saline clamps performed in Chapter III. 
Experiments were performed 7 days after surgical implantation of carotid 
artery and jugular vein catheters. Mice were fasted for 5 h prior to the onset 
of the clamp. Primed-continuous infusion of [3-
3
H]glucose began at t= -90 
min. At t= 0 min saline was infused in lieu of insulin. Basal blood draws 
occurred at -15 and -5 min and blood glucose was measured at 10 min 
intervals starting at t= 0 min. Red blood cell replacement maintained 
hematocrit during the study period. 2[
14
C]glucose was injected 
intravenously at t= 120 min to measure tissue specific glucose uptake.  
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Figure 3.3 – Protocol for the glucose tolerance test performed in Chapter 
III. Experiments were performed 7 days after surgical implantation of 
carotid artery and gastric catheters. The gastric catheter permits 
physiological absorption of glucose without inducing a stress response. 
Mice were fasted for 5 h prior to the outset. At t= 0 min 2g/kg body weight 
of glucose was administered via the gastric catheter. Blood glucose was 
assessed at t= 5, 10, 15, 20, 30, 45, 60, 90, and 120 min. Plasma insulin was 
assessed at t= 10, 20, 30, 60, and 120 min. Fasting arterial glucose and 
insulin were measured at t = -5 min.  
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Table 3.1 
Characteristics of muscle specific VEGF deficient mice 
 
mVEGF
+/+
 mVEGF
-/-
 
N 8 9 
Weight (g) 26.1 ± 1.5 25.3 ± 0.9 
Fat (g) 2.2 ± 0.30 2.1 ± 0.20 
Muscle (g) 18.5 ± 1.2 18.0 ± 0.7 
Gastrocnemius capillary density
† 
1.00 ± 0.2 0.41 ± 0.1* 
Cardiac capillary density
† 
1.00 ± 0.06 0.52 ± 0.06* 
Mean arterial pressure (mmHg) 117 ± 4.0 108 ± 4.4 
Cardiac output (mL/min) 23.9 ± 1.7 21.0 ± 0.6 
Fractional shortening (%) 46.6 ± 1.2 18.7 ± 2.0* 
Ejection fraction (%) 78.9 ± 1.3 38.5 ± 3.7* 
LV diastolic volume (µL) 47.3 ± 4.0 89.5 ± 7.0* 
LV mass (mg) 54.6 ± 5.5 66.9 ± 3.4* 
Data are expressed as mean ± SE. 
†
Capillary density is quantified by the number of CD 
31+ structures normalized to mVEGF
+/+
 mice.  LV is the abbreviation for left ventricular. 
*P-value ≤ 0.05. 
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Figure 3.4- (A) VEGF-A protein levels in tissue homogenates from cardiac and 
skeletal muscle and (B) VEGF-A plasma concentration. Skeletal muscle VEGF 
levels were quantified in the gastrocnemius. Values are expressed as means ± 
SE. n = 5, *P-value ≤ 0.05 vs. mVEGF(+/+). 
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Table 3.2 
Fasting and insulin clamp characteristics 
 
mVEGF
+/+
 mVEGF
-/-
 
Arterial glucose (mg/dL)   
      Basal 119 ± 7 113 ± 5 
      Insulin clamp 145 ± 3 151 ± 3 
Arterial insulin (ng/mL)   
      Basal 1.2 ± 0.2 1.6 ± 0.3 
      Insulin clamp 4.2 ± 0.8 5.2 ± 0.5 
Free fatty acids (mmol/L)   
      Basal 0.76 ± 0.10 0.76 ± 0.10 
      Insulin clamp 0.18 ± 0.04 0.17 ± 0.01 
Liver glycogen (mg glucose/g liver) 10.0 ± 2.3 18.6 ± 2.1* 
Fasting liver glycogen (mg glucose/g liver) 3.90 ± 2.0 8.30 ± 1.9 
Glycogen synthase activity
†
 0.06 ± 0.007 0.09 ± 0.015 
Liver glycogen was measured from tissue excised immediately after the insulin clamp 
and fasting liver glycogen was assessed immediately after the 7.5 h saline infused 
experiments. 
†
Liver glycogen synthase activity was determined after the insulin clamp 
and presented as the ratio of glycogen synthase activity in the absence and presence of 
glucose-6-phosphate. Data are expressed as mean ± SE. n= 7-9, *P-value ≤ 0.05. 
  
67 
 
 
  
0
10
20
30
40
50
E
n
d
o
R
a
 (
m
g
·k
g
-1
·m
in
-1
) 
Basal           Clamp 
0
10
20
30
40
50
R
d
 (
m
g
·k
g
-1
·m
in
-1
) 
Basal            Clamp 
* 
0
10
20
30
In
su
li
n
-S
ti
m
u
la
te
d
 R
d
 
(m
g
·k
g
-1
·m
in
-1
) 
WT
VEGF-KO
* 
0
50
100
150
200
250
A
rt
er
ia
l 
G
lu
co
se
 (
m
g
·d
L
-1
) 
WT
KO
0
10
20
30
40
50
60
-30 0 30 60 90 120
G
IR
 (
m
g
·k
g
-1
·m
in
-1
) 
Time (min) 
Figure 3.5 - Arterial glucose (A) and glucose infusion rate (B) during the 
hyperinsulinemic-euglycemic clamp. Mice were fasted 5 h prior to the onset of the 
clamp. Blood glucose was maintained at ~150 mg/dl during steady-state (80-120 
min) and the time course is displayed to demonstrate quality of the clamp. 50% 
glucose was infused to maintain euglycemia. Endogenous glucose production 
(EndoRa - C), whole-body glucose disappearance (Rd - D), and insulin-stimulated 
glucose disposal (E) determined during the hyperinsulinemic-euglycemic clamp. 
Basal values were determined from samples at t= -15 and -5 min prior to the onset 
of the clamp and insulin clamp levels were calculated from steady-state values 
(80-120 min).  Insulin-stimulated Rd was calculated by subtracting the basal Rd 
from the clamp Rd, which measures the increase in insulin-stimulated glucose 
disposal. Data are expressed as mean ± SE, n= 7-9,*P-value ≤ 0.05 vs. 
mVEGF
(+/+)
. 
 
* 
mVEGF
+/+
 
mVEGF
-/-
 
mVEGF
+/+
 
mVEGF
-/-
 
A C D 
B E 
68 
 
 
  
0
2
4
6
R
el
a
ti
v
e 
E
x
p
re
ss
io
n
 
    PEPCK                     G6Pase 
Series1
Series2
mVEGF
+/+
 
mVEGF
-/-
 * 
D 
A 
0
50
100
150
200
250
300
350
A
rt
er
ia
l 
G
lu
co
se
 (
m
g
·d
L
-1
) 
WT
KO
mVEGF
+/+
 
 mVEGF
-/-
 
0
2
4
6
0 30 60 90 120
P
la
sm
a
 I
n
su
li
n
 (
n
g
·m
L
-1
) 
Time (min) 
* 
B 
0
1000
2000
3000
4000
5000
A
U
C
 g
lu
co
se
 (
[m
g
·d
L
-1
]·
m
in
) 
* 
C 
Figure 3.6 - Glucose tolerance was determined (A) and corresponding plasma 
insulin levels quantified (B) on 5 h fasted mice. The area under the curve (C) was 
determined from 0-30 min and normalized to fasting arterial glucose 
concentration. RT-PCR was performed on hepatic RNA extracts from mice fasted 
for 5 h for the relative expression of the gluconeogenic genes PEPCK and G6Pase 
(D). Values are expressed as mean ± SE. n=5-6, *P-value ≤ 0.05 vs. mVEGF(+/+). 
 
69 
 
  
0
30
60
90
120
150
Soleus
R
g
 (
µ
m
o
l·
1
0
0
g
ti
ss
-1
· 
m
in
-1
) 
*  
0
10
20
30
40
50
Gastrocnemius
* 
0
100
200
300
400
500
600
Heart
R
g
 (
µ
m
o
l·
1
0
0
g
ti
ss
-1
·m
in
-1
) 
wt
ko
* 
mVEGF
+/+
 
 mVEGF
-/-
 
A 
B 
Figure 3.7 - Insulin-stimulated metabolic index (Rg) in skeletal (A) and cardiac 
(B) muscle. To quantify insulin-stimulated Rg, we performed a time control in a 
cohort of mVEGF
(+/+)
 and mVEGF
(-/-)
 mice in which saline was infused in lieu of 
insulin to quantify basal Rg. The Rg values from the saline infusion were averaged 
and subtracted from the Rg values during the insulin clamp. Data are expressed as 
mean ± SE. n= 7-9, *P-value ≤ 0.05 vs. mVEGF(+/+). 
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Table 3.3 
Fasting Muscle Glucose Uptake during the Saline Clamp 
 mVEGF
+/+
 mVEGF
-/-
 
Soleus 
Rg (µmol·100gtissue
-1
·min
-1
) 
 
 
9.5 
 
7.6 
Gastrocnemius 
Rg (µmol·100gtissue
-1
·min
-1
) 
 
 
5.4 
 
3.4 
Heart 
Rg (µmol·100gtissue
-1
·min
-1
) 
 
 
127.5 
 
260.5 
Mice were fasted 5 h prior to the onset of the saline clamp. Tissues were collected after 
2.5 h saline infusion. Data are expressed as mean ± SE and n= 7-9.  
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Figure 3.8 - Skeletal muscle and hepatic insulin signaling after the 
hyperinsulinemic-euglycemic clamp. Western blot analysis was performed on 
extracts of the gastrocnemius and liver for the phosphorylation of Akt at Ser473 
and total Akt. Infrared imaging was performed on 4-12% SDS-PAGE gel in 
skeletal muscle (A and C) and liver (E). Immunoprecipitation (IP) from 
gastrocnemius extracts were performed with total IRS-1 then immunoblots (IB) 
were completed for phospho-IRS-1 at Tyr612 and the p85 subunit of PI 3-kinase 
(A). Insulin-stimulated p85 association with phospho-IRS-1 was quantified as the 
ratio of p85 to phospho-IRS-1 (B). Insulin activation of Akt (C and E) was 
quantified as the ratio of phospho-Akt to total Akt in skeletal muscle (D) and liver 
(F). GAPDH was used as a loading control. Data are expressed as mean ± SE, n= 
5-6, *P-value ≤ 0.05 vs. mVEGF(+/+). 
 
72 
 
  
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Basal Insulin 10mU/ml
2
-D
G
 u
p
ta
k
e 
(µ
m
o
l·
g
-1
·h
-1
) 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Basal Insulin 10mU/ml
WT
VEGF-KO
Soleus Extensor digitorum longus 
mVEGF
+/+
 
 
 mVEGF
-/-
 
A B 
Figure 3.9 - Skeletal muscle insulin action was assessed in the isolated soleus (A) 
and extensor digitorum longus (B). Mice were fasted for 5 h prior to the excision 
of the muscles. Values are expressed as mean ± SE, n= 6. 
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Chapter IV 
 
GAIN OF VASCULAR FUNCTION: PHARMACOLOGICALLY TARGETING 
THE EXTRAMYOCELLULAR BARRIERS TO MUSCLE GLUCOSE UPTAKE 
WITH THE HORMONE RELAXIN 
 
Aims 
The goal of Chapter IV was to determine whether pharmacologically targeting the 
extramyocellular barriers to MGU with the hormone relaxin rescues HF diet-induced 
skeletal muscle insulin resistance. Previous work has established a critical role for 
glucose and insulin delivery in the regulated process of insulin-stimulated MGU.  
Furthermore, extracellular matrix remodeling and vascular dysfunction are involved in 
the pathogenesis of insulin resistance and the greater metabolic syndrome. There is a 
need for therapeutic options to treat insulin resistance with a physiological approach that 
has the potential to improve both metabolic and vascular dysfunction associated with 
obesity. To address this, lean and HF-fed C57BL/6J mice were studied to determine the 
hemodynamic and metabolic effects of relaxin during a insulin clamp. To investigate the 
therapeutic potential of relaxin C57BL/6J mice were fed a HF diet for 13 weeks with the 
final 3 weeks of the diet mice received a continuous infusion of relaxin or vehicle via 
osmotic minipumps. The hypothesis tested was that a chronic intervention with relaxin 
will reverse the extramyocellular adaptations to a HF diet, thus ameliorating diet-induced 
skeletal muscle insulin resistance.  
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Introduction 
Insulin resistance precedes the development of type 2 diabetes and it is associated 
with cardiovascular disease. Recent evidence suggests that muscle insulin resistance 
coincides with extramyocellular adaptations including extracellular matrix (ECM) 
remodeling and capillary rarefaction (51, 82, 87, 111). Kang et al. established that the 
accumulation of ECM proteins and lower capillary number correspond to muscle insulin 
resistance in HF-fed mice (87, 111). The vascular and ECM abnormalities associated 
with obesity provide novel therapeutic targets to simultaneously treat insulin resistance 
and its co-aggregates.  
The hemodynamic action of insulin is fundamental to skeletal muscle metabolism 
during insulin stimulation (141, 142). Hyperinsulinemia increases skeletal muscle 
microvascular blood volume, thus, enhancing nutrient and hormone flux to this tissue 
(37, 45, 84). Previous studies estimated that 40% of insulin-stimulated MGU was a result 
of increased muscle perfusion and that this hemodynamic response is diminished in 
insulin resistant individuals (36, 57). Studies applying metabolic control analysis 
demonstrated that the vascular delivery of glucose to the muscle is a major limitation to 
insulin-stimulated MGU (14, 17). HF-fed mice have attenuated vascular insulin signaling 
that precedes the impairment in insulin responsive tissues such as skeletal muscle, liver, 
and adipose tissue (50). Kubota et al. showed that impaired endothelial insulin signaling, 
in mice lacking endothelial insulin receptor substrate 2, prevented eNOS activation and 
resulted in decreased muscle perfusion, substrate delivery, and MGU during steady-state 
hyperinsulinemia (48).  
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Relaxin (Rlx), a 6-kDa protein hormone, has potent vasodilatory and antifibrotic 
actions (101, 102, 143-145). Rlx augments circulating vascular endothelial growth factor-
A (VEGF) concentrations, which is essential to the vasodilatory response (95). 
Furthermore, Rlx induced VEGF expression stimulates the integration of  bone-marrow 
derived endothelial cells into sites of vasculogenesis to enhance vessel growth (104, 105). 
In experimental models of type I diabetes and hypertension, Rlx attenuated the fibrotic 
response in cardiac and renal tissues respectively (101, 102).  An important mechanism 
for the antifibrotic actions of Rlx is blunted TGFβ signaling, which can reduce collagen 
(Col) deposition (96-99). Rlx regulation of matrix metalloproteinases (MMP) -2 and -9 
activities has been shown to be important to the ECM remodeling mechanism of Rlx and 
the acute vasodilatory response (94, 96, 99). The pleiotropic actions of Rlx provide an 
intriguing therapeutic candidate for insulin resistance.  
The goal of the current investigation was to determine the viability of Rlx 
intervention in rescuing muscle insulin resistance. The hypotheses tested herein are: (1) 
acute Rlx infusion will enhance skeletal muscle perfusion and insulin action in lean but 
not HF-fed mice; and chronic Rlx intervention in HF-fed mice will (2) reverse muscle 
insulin resistance and (3) enhance endothelial reactivity and augment skeletal muscle 
capillarity.  
 
Experimental Design 
Male 6-week old C57BL/6J mice (Jackson Laboratory) were either placed on a 
chow or HF diet containing 5.5% or 60% calories as fat respectively. In Protocol 1 
(Figure 4.1), 13 week chow-fed and HF-fed mice had a primed (10µg) continuous 
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infusion (15µg/h) with recombinant H-2 Rlx (15µg/h; H2-relaxin, Corthera, Inc, a 
subsidiary of Novartis Pharmaceuticals Corp.) or Vehicle (20mM sodium acetate, pH 5.0) 
for 6.5 h total. The infusion of Rlx or Vehicle began 1 h after the onset of the fast and 
lasted for the duration of the insulin clamp. In Protocol 2 (Figures 4.2 and 4.3), mice were 
fed a HF diet for 13 weeks. At week 10 of HF-feeding osmotic minipumps (Alzet models 
2001 and 2002; replaced after 2 weeks) were implanted subcutaneously to deliver Rlx at 
a rate of 1 mg·kg
-1
·day
-1 
or Vehicle. The HF-fed cohort in Protocol 1 permitted a control 
for any potential acute actions of relaxin in Protocol 2 during the insulin clamps. In all 
protocols, insulin clamps were performed to assess insulin action (Figures 4.1 and 4.3) 
and aortic ring reactivity tests to assess vascular function. See Chapter II for detailed 
methods.  
 
Results 
Protocol 1: Acute Rlx infusion enhances insulin-stimulated MGU in chow-fed but 
not HF-fed mice.  
Glucoregulatory: To test the hypothesis that a 6.5 h Rlx infusion enhances insulin-
stimulated MGU in chow-fed mice, insulin clamps were performed in 5 h fasted mice.  
There was no difference in body weight between treatment groups (Table 4.1). The acute 
chow-fed Rlx group had greater fasting arterial insulin; however, no change in fasting 
arterial glucose was present (Table 4.1). Insulin clamps were performed to determine in 
vivo muscle insulin action in conscious unrestrained mice (15). During the steady-state 
period of the insulin clamp (80-120 min), Rlx treated mice required a higher GIR to 
maintain euglycemia compared to Vehicle infused mice (p≤0.05; Figure 4.4A). The 
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increase in GIR was independent of changes in the suppression of endoRa (Figure 4.4B). 
The enhanced GIR in the Rlx group was due to an augmented whole-body glucose 
disappearance (Rd) during the clamp steady-state period (p≤0.05; Figure 4.4B). The Rg in 
the Rlx infusion group was greater in the gastrocnemius, superior vastus lateralis (SVL), 
and heart (p≤0.05; Figure 4.4C). The in vivo muscle glucose flux data coincided with 
augmentation of the ratio of phospho-Akt to total Akt in the gastrocnemius (p≤0.05; 
Figure 4.5B). 
The acute Rlx infusion of Protocol 1 was repeated in HF-fed mice. In contrast to 
the chow-fed mice, there was no difference in insulin action and glucose fluxes between 
the Vehicle and Rlx infused groups. There was no difference in body weight or arterial 
glucose and insulin levels in the fasted and clamp states (Table 4.1). The GIR during the 
insulin clamps were equal (Figure 4.6A). The endoRa and Rd were comparable between 
groups in the basal and insulin clamp states (Figure 4.6B). The Rg data corresponded to 
the flux analysis with no difference in the gastrocnemius, SVL, or heart (Figure 4.6C). 
HF-fed mice are resistant to the acute effects of Rlx. 
Ex vivo glucose uptake was determined in isolated muscle from chow-fed mice 
that underwent a 6.5 h Rlx infusion (Protocol 1) identical to the insulin clamp cohorts. 
Isolated glucose uptake was performed only in the chow-fed mice due to the enhanced 
insulin clamp Rg. Glucose uptake in isolated muscle removes the vascular delivery barrier 
of MGU during hyperinsulinemia. There was no difference in basal or insulin-stimulated 
glucose uptake in isolated soleus or extensor digitorum longus (EDL) muscles between 
groups (Figure 4.5A).  
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Vascular: The 6.5 h Rlx infusion enhanced the hemodynamic response to insulin in 
chow-fed mice. Endothelial-dependent aortic ring relaxation in the Rlx group was 
amplified with no difference in smooth muscle-dependent relaxation (p≤0.05; Figure 
4.4D). The acute enhancement in endothelial specific vascular reactivity was absent in 
the HF-fed cohort (Figure 4.6D). Muscle blood flow was increased in the Rlx group as 
indicated by a 2.5-fold increase in gastrocnemius microsphere content (p≤0.05; Figure 
4.5C). The 6.5 h Rlx infusion resulted in a 2.5-fold increase in MMP-9 and pro-MMP-2 
activities (p≤0.05; Figure 4.5D).  
 
Protocol 2: Rlx intervention reverses diet-induced insulin resistance and the 
associated extramyocellular adaptations.  
Glucoregulatory: To test the hypothesis that intervention with Rlx can reverse muscle 
insulin resistance and the extramyocellular adaptations to a HF diet, mice were treated 
with Rlx or Vehicle for the final 3 weeks of a 13 week HF diet. Rlx intervention did not 
alter body weight or composition (Table 4.2). Furthermore, the 3 week Rlx treatment did 
not result in differences in mean arterial blood pressure or cardiac morphology (Table 
4.2).  Insulin clamps were performed after the 3 week intervention. Fasting (5 h) arterial 
glucose was lower in the Rlx treated mice (p≤0.05; Table 4.2). During the steady-state 
period of the insulin clamp, the Rlx group required a higher GIR to maintain euglycemia 
at ~150 mg/dL (p≤0.05; Figure 4.7A). Rlx did not affect fasting glucose fluxes. Insulin 
suppressed endoRa during the steady-state period to a greater extent with Rlx intervention 
(p≤0.05; Figure 4.7B), suggesting improved hepatic insulin action. The greater GIR in the 
Rlx treated group corresponded to enhanced whole-body Rd during the steady-state 
79 
 
period of the insulin clamp (p≤0.05; Figure 4.7B). Rg was elevated in the gastrocnemius 
and SVL in the Rlx group compared to Vehicle during hyperinsulinemia (p≤0.05) and 
cardiac muscle Rg tended to be higher (p=0.1; Figure 4.7C). Skeletal muscle and hepatic 
phospho-Akt to total Akt ratio tended to be higher after the Rlx intervention but 
differences were not significant (Figure 4.8A). 
 Ex vivo glucose uptake in isolated soleus and EDL showed no difference between 
the Vehicle or Rlx groups (Figure 4.7D). This suggests that the extramyocellular effects 
of Rlx are key to the effectiveness of Rlx intervention in HF-fed mice. 
Extracellular Matrix Remodeling: Col-III and -IV levels were equivalent in skeletal 
muscle between treatment groups (Figure 4.8B and C). The improvement in hepatic 
insulin action with Rlx treatment was associated with reduced col-III (p≤0.05; Figure 
4.8D). Cardiac col-III and -IV were increased in response to the HF diet, but were 
reduced by ~50% and ~65% respectively after the 3 week Rlx intervention (p≤0.05; 
Figure 4.9A and B). This effectively normalized these ECM proteins to levels of lean 
mice. The abatement in cardiac ECM protein associated with a reduction in SMAD2 
phosphorylation (p≤0.05; Figure 4.9C), which is a marker of TGFβ receptor downstream 
activation.   
Vascular: The enhanced muscle insulin action in Rlx treated mice was associated with a 
2-fold expansion of skeletal muscle capillary density (p≤0.05; Figure 4.10A). Improved 
vascular reactivity was present after the Rlx intervention as indicated by an augmented 
endothelial-dependent aortic relaxation (p≤0.05; Figure 4.10C). There was no difference 
in smooth muscle-dependent relaxation in response to sodium nitroprusside and no 
significant change in the vasculature response to phenylephrine (PE) (Figure 4.10C and 
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D).  A potential common mechanism for the changes in skeletal muscle capillary density 
and endothelial-dependent relaxation is the elevated arterial VEGF concentrations after 3 
weeks of continuous Rlx administration (p≤0.05; Figure 4.10B). 
 
Discussion 
These studies demonstrate for the first time that infusion of the hormone Rlx 
acutely augments muscle perfusion and insulin-stimulated MGU in lean, healthy 
C57BL/6J mice. There is no such acute Rlx effect in HF-fed mice. However, results show 
that a 3 week Rlx intervention in HF-fed ameliorates the metabolic and cardiovascular 
dysfunction. It is important to recognize that the potent metabolic effects of Rlx were 
absent in isolated muscle fibers, regardless of whether Rlx was administered acutely in 
lean mice or as a chronic intervention in HF-fed mice. The data from isolated muscle 
support the hypothesis that Rlx diminishes the extramyocellular barriers to MGU during 
hyperinsulinemia. 
Baron et al. demonstrated that the co-infusion of insulin and a vasodilator in 
healthy subjects resulted in a synergistic effect to enhance limb blood flow and muscle 
glucose uptake (84). In congruence with this clinical study, the acute Rlx infusion in the 
chow-fed mice of Protocol 1 increased steady-state Rd and muscle Rg during the insulin 
clamp.  The Rlx infused mice had greater muscle microsphere deposition at the 
termination of the insulin clamp and enhanced aortic ring relaxation suggesting a greater 
hemodynamic response to insulin. The amplified muscle blood flow increases insulin and 
glucose access to the muscle interstitium. This would predictably enhance insulin action 
as supported by augmented in vivo skeletal muscle insulin signaling. The increased pro-
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MMP-2 and MMP-9 activities were consistent with the acute vasodilatory mechanisms of 
Rlx (94).The equivalent basal and insulin-stimulated glucose uptake in isolated muscle 
suggests that the primary mechanism for the enhanced muscle Rg was independent of 
direct actions of Rlx on the myocyte. 
The 3 week Rlx intervention in Protocol 2 was effective in improving insulin 
action in HF-fed mice. The improvement in glucose homeostasis in both the fasted and 
insulin-stimulated state is speculated to be a result of the actions unique to Rlx that 
improve vascular adaptations to the HF diet. The isolated MGU data support this 
conclusion. Potentially other extramyocellular factors that require long-term treatment, 
such as an increase in plasma VEGF, could be necessary for the in vivo glucoregulatory 
effects of Rlx that are absent ex vivo. Furthermore, Rlx has been shown to antagonize 
angiotensin II action (146) and the renin-angiotensin system has been implicated in the 
pathogenesis of skeletal muscle capillary rarefaction and insulin resistance (53). The 
glucoregulatory and vascular adaptations that are present with the chronic Rlx 
administration are notably absent in the HF-fed cohort of Protocol 1. This may provide 
insight into the mechanism of Rlx action in HF-fed mice. It would suggest that an 
adaptive process, rather than acute activation, is required to overcome the impairments in 
insulin action in HF-fed mice. Rlx intervention has previously been shown to ameliorate 
endothelial dysfunction in models of hypertension (95, 145, 147). In the current model of 
HF diet-induced insulin resistance, Rlx improved endothelial function.  The improvement 
in endothelial reactivity did not occur in HF-fed mice that underwent an acute Rlx 
infusion, suggesting long-term administration is necessary to overcome the vascular 
impairment associated with a HF diet (148). Rlx acts through an eNOS dependent 
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pathway to cause vascular relaxation. It is speculated that the vascular remodeling and 
impaired eNOS function present in HF-fed mice nullifies the acute Rlx effect in the HF-
fed mice in Protocol 1 (149). Consistent with this finding, acute administration of Rlx 
does not ameliorate hypertension in spontaneously hypertensive rats (146). Additionally, 
Rlx treated mice had a ~2-fold increase in skeletal muscle capillary density. Capillary 
rarefaction and endothelial dysfunction associated with obesity are critical to the 
pathogenesis of skeletal muscle insulin resistance (38, 54, 55, 150). The actions of Rlx on 
the vasculature may enhance the hemodynamic response to hyperinsulinemia, thus 
augmenting microvascular perfusion. An increase in muscle blood volume would 
increase the surface area for insulin and glucose diffusion, in addition to other hormones 
and nutrients (14, 45, 48, 59).  The likely mechanism for the improved endothelial 
function and expansion of skeletal muscle capillary density is the elevation in circulating 
VEGF, which has been shown to be critical to the sustained vasodilatory and angiogenic 
actions of Rlx (95, 104, 105).  
The efficacy of Rlx to enhance MGU during hyperinsulinemia acutely in lean and 
chronically in HF-fed mice was independent of an interaction directly with the insulin 
receptor. Originally, Rlx was characterized to be part of the insulin family of proteins due 
to their common two-chain structure. More recent data demonstrated that Rlx diverged 
from the insulin family early in vertebrate evolution forming a separate protein and 
receptor family (151). There is no evidence to support the cross-reactivity of Rlx with the 
insulin receptor, as Rlx does not activate protein kinase receptors (152). The metabolic 
effects demonstrated in the current study were likely due to extramyocellular and 
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extrahepatic adaptations to Rlx. Notably, the specific receptor for Rlx, RXFP1, has not 
been identified in skeletal myocytes or hepatocytes (152).  
ECM deposition occurs in skeletal muscle, liver, and cardiac tissue of HF-fed 
rodents (87, 153, 154) and insulin resistant humans (111, 153, 155, 156). The interaction 
of collagen proteins with the integrin receptors has been linked to the development of 
hepatic and skeletal muscle insulin resistance (87). In the current studies, Rlx reversed 
the deposition of hepatic col-III, though there was no difference in hepatic col-IV (data 
not shown). It is speculated that the improved hepatic insulin action was related to the 
reduction in col-III and the potential interaction with the hepatic integrin receptors. 
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are associated with the 
development and progression of fibrosis in type 2 diabetes and subsequent impairments 
in hepatic insulin action (153, 157). Previously, col-III and –IV have been shown to be 
elevated in muscle of HF-fed mice and humans (87, 111); however, there was no 
difference in these collagen species in skeletal muscle in the current model, perhaps 
relating to differences in diet duration. Although col-III and -IV are major components of 
the extracellular matrix there are other distinct matrix proteins that could have been 
altered.  
Rlx intervention diminished col-III and -IV accumulation in the heart, which is 
consistent with the antifibrotic effects of long-term Rlx treatment shown in rodent models 
of type 1 diabetes (101) and hypertension (102). The decreased cardiac ECM proteins 
after the Rlx treatment was likely a consequence of Rlx inhibiting the downstream 
activation of SMAD2 by transforming growth factor-β (TGFβ) (96, 97, 99). The 
diminished cardiac col-III and –IV and ameliorated endothelial dysfunction in Protocol 2 
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emphasizes that Rlx may be efficacious in the treatment of the broader dysfunction 
associated with the metabolic syndrome. 
Macro- and microangiopathies correlate with insulin resistance (158, 159) leading 
to impaired tissue perfusion, which is a key component of the etiology of diabetes-related 
tissue and organ damage (46). Furthermore, endothelial dysfunction and capillary 
rarefaction contribute to hypertension and insulin resistance, both of which are 
components of the metabolic syndrome and increase the risk of cardiovascular mortality 
(46, 150, 160). Thus, it is critical to consider the common underlying vascular 
pathologies to develop novel intervention strategies to treat the metabolic syndrome. 
However, a critical consideration for the long-term clinical administration of a vascular 
proliferative compound is the potential exacerbation of tumor development and 
metastasis. This is particularly important because there is a positive association between 
insulin resistance and many types of cancers (161). It is possible that chronic exposure to 
Rlx for the treatment of insulin-resistance may exacerbate outcomes in cancer patients. 
Notably, Rlx is expressed at higher levels in prostate cancer and correlates to metastatic 
potential and diminished survival (162) and the inhibition of RXFP1 has been 
investigated as a potential therapeutic target (163).  
These studies demonstrate the effectiveness of Rlx in targeting the 
extramyocellular barriers to MGU for the treatment of insulin resistance. Intervention 
with the hormone Rlx targets multiple physiological systems to ameliorate cardiac and 
hepatic collagen accumulation, increase skeletal muscle capillary density, and improve 
diet-induced endothelial dysfunction. These effects contribute to the enhancement of in 
vivo insulin action in HF-fed mice and require an extended treatment period to mitigate 
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these extramyocellular barriers to insulin-stimulated MGU. The results not only highlight 
the efficacy of Rlx in the correction of muscle insulin resistance, but also demonstrate the 
potential therapeutic value of Rlx in reversing fibrosis and vascular dysfunction 
associated with a HF diet.  
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Figure 4.1 – Protocol 1: Experimental setup for the hyperinsulinemic-
euglycemic clamps performed in Chapter IV. Experiments were performed 
7 days after surgical implantation of carotid artery and jugular vein 
catheters. Mice were fasted for 5 h prior to the onset of the clamp. A 
primed-continuous infusion of relaxin began at t= -240 min. Primed-
continuous infusion of [3-
3
H]glucose began at -90 min. At t= 0 min insulin 
was elevated to postprandial levels. Basal blood draws occurred at t= -15 
and -5 min and blood glucose was measured at 10 min intervals starting at 
t= 0 min. Variable glucose was infused to maintain euglycemia at ~150 
mg/dL and red blood cell replacement maintained hematocrit during the 
study period. 2[
14
C]glucose was injected intravenously at t= 120 min to 
measure tissue specific glucose uptake.  
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Figure 4.2 – Protocol 2: Diet and treatment time-course for the 
chronic relaxin intervention in high-fat fed C57BL/6J mice. The 
onset of the high-fat diet began at 6 weeks of age and lasted for 
13 weeks. Relaxin or Vehicle was administered at a rate of 1 
mg·kg
-1
·day
-1
 and began at week 10 of the high fat diet. Relaxin 
and Vehicle were administered continuously for the final 3 
weeks of high fat-feeding, at which time hyperinsulinemic-
euglycemic clamps were performed.  
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Figure 4.3 – Protocol 2: Experimental setup for the hyperinsulinemic-
euglycemic clamps performed in Chapter IV. Experiments were performed 
7 days after surgical implantation of carotid artery and jugular vein 
catheters. Mice were fasted for 5 h prior to the onset of the clamp. Primed-
continuous infusion of [3-
3
H]glucose began at t= -90 min. At t= 0 min 
insulin was elevated to postprandial levels. Basal blood draws occurred at 
t= -15 and -5 min and blood glucose was measured at 10 min intervals 
starting at t= 0 min. Variable glucose was infused to maintain euglycemia at 
~150 mg/dL and red blood cell replacement maintained hematocrit during 
the study period. 2[
14
C]glucose was injected intravenously at t= 120 min to 
measure tissue specific glucose uptake.  
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Table 4.1 
Insulin Clamp Characteristics in Protocol 1 
 
 
Vehicle Relaxin 
Protocol 1: 
Chow-fed Mice 
n 9 8 
Weight (g) 30.0 ± 0.3 29.5 ± 0.3 
Arterial glucose (mg/dL)   
        Basal 130 ± 7 129 ± 3 
        Clamp 148 ± 2 149 ± 3 
Arterial insulin (ng/mL)   
        Basal 0.8 ± 0.1 1.2 ± 0.1* 
        Clamp 4.6 ± 0.3 4.6 ± 0.3 
Protocol 1:   
HF-fed Mice 
n 5 5 
Weight (g) 38.6 ± 2 40.1 ± 1 
Arterial glucose (mg/dL)   
        Basal 132 ± 9 126 ± 11 
        Clamp 148 ± 3 146 ± 4 
Arterial insulin (ng/mL)   
        Basal 5.2 ± 1 7.1 ± 2 
        Clamp 10.9 ± 2 12.6 ± 2 
Mice were fasted 5 h prior to the onset of the insulin clamp. The Rlx infusion occurred 
for a duration of 6.5 h through the insulin clamp. Insulin clamp arterial glucose was an 
average of 80-120 min and arterial insulin was an average of t= 100 and 120 min. Data 
are expressed as mean ± SE. *P-value ≤ 0.05 
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  Figure 4.4 - Protocol 1, chow-fed: Hyperinsulinemic-euglycemic clamps, 
glucose flux analysis, and vascular reactivity after a 6.5 h Rlx or Vehicle 
infusion in lean mice. (A) Glucose infusion rate (top) and arterial glucose 
(bottom) during the insulin clamp. Mice were fasted 5 h prior to the onset of 
the clamp. Blood glucose was maintained at ~150 mg/dL during steady-state 
(80-120 min) and the time course is displayed to demonstrate quality of the 
clamp. 50% glucose was infused to maintain euglycemia. Endogenous 
glucose production and whole-body glucose disposal (B-EndoRa and Rd) 
during the insulin clamp. Basal values are an average of t= -15 and -5 min 
and the insulin clamp values are an average of 80-120 min (steady-state). 
(C) Glucose metabolic index (Rg) after the insulin clamp in the 
gastrocnemius, SVL (superior vastus lateralis), and heart. Endothelial and 
smooth muscle dependent relaxation (D) in aortas excised from mice after 
the insulin clamp in response to carbachol (Cch) and sodium nitroprusside 
(SNP) respectively. Data are expressed as mean ± SE, n= 8-9,*P-value ≤ 
0.05. 
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Figure 4.5 - Protocol 1, chow-fed: Isolated MGU, insulin signaling, muscle 
perfusion, and MMP activation after the 6.5 h Rlx or Vehicle infusion. 
Isolated muscle glucose uptake (A) on the soleus and EDL (extensor 
digitorum longus). Mice were fasted for 5 h and muscles excised after the 
6.5 h Rlx infusion. Western blot analysis of the activation status of Akt (B) 
after the insulin clamp analyzed as the ratio of phosphorylated Akt to total 
Akt. Microsphere content in the gastrocnemius (C) after the insulin clamp. 
Gelatin zymogram to determine matrix metalloproteinase-2 and -9 activitity 
(D) in gastrocnemius muscle after the insulin clamp. AU represents arbitrary 
units. AU represents arbitrary units. Data are expressed as mean ± SE, n= 5. 
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Figure 4.6 - Protocol 1, high fat-fed: Hyperinsulinemic-euglycemic clamps, 
glucose flux analysis, and vascular reactivity after a 6.5 h Rlx or Vehicle 
infusion in HF-fed mice. (A) Glucose infusion rate (top) and arterial glucose 
(bottom) during the insulin clamp. Mice were fasted 5 h prior to the onset of 
the clamp. Blood glucose was maintained at ~150 mg/dL during steady-state 
(80-120 min) and the time course is displayed to demonstrate quality of the 
clamp. 50% glucose was infused to maintain euglycemia. Endogenous 
glucose production and whole-body glucose disposal (B-EndoRa and Rd) 
during the insulin clamp. Basal values are an average of t= -15 and -5 min 
and the insulin clamp values are an average of 80-120 min (steady-state). 
(C) Glucose metabolic index (Rg) after the insulin clamp in the 
gastrocnemius, SVL (superior vastus lateralis), and heart. Endothelial and 
smooth muscle dependent relaxation (D) in aortas excised from mice after 
the insulin clamp in response to carbachol (Cch) and sodium nitroprusside 
(SNP) respectively. Data are expressed as mean ± SE, n= 5. 
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Table 4.2 
Treatment Group Characteristics in Protocol 2 
 
Vehicle Relaxin 
n 13 11 
Weight (g) 34.8 ± 0.8 34 ± 1.0 
Fat (%) 16.5 ± 1.3 15.6 ± 2.5 
Muscle (%) 65.1 ± 0.7 65.7 ± 1.5 
Arterial glucose (mg/dL)   
        Basal 145 ± 6 130 ± 5* 
        Clamp 151 ± 2 148 ± 3 
Arterial insulin (ng/mL)   
        Basal 1.8 ± 0.3 2.1 ± 0.4 
        Clamp 6.2 ± 0.9 7.5 ± 0.9 
Free fatty acids (mmol/L)   
        Basal 1.10 ± 0.08 0.80 ± 0.10 
        Clamp 0.44 ± 0.05 0.42 ± 0.03 
Mean arterial pressure (mmHG) 126 ± 3 131 ± 3 
Cardiac output (mL/min) 21 ± 1 21 ± 2 
Ejection fraction (%) 81 ± 1 77 ± 2 
Fractional shortening (%) 48 ± 0.6 45 ± 0.1* 
LV mass (mg) 62.5 ± 3 63.9 ± 5 
LV diastolic volume (µL) 41 ± 3 43 ± 5 
Mice were fasted 5 h prior to the onset of the insulin clamp. Insulin clamp arterial 
glucose was an average of 80-120 min. Arterial insulin and free fatty acids were an 
average of t= 100 and 120 min. LV is the abbreviation for left ventricular. Data are 
expressed as mean ± SE. *P-value ≤ 0.05 
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Figure 4.7 - Protocol 2: Hyperinsulinemic-euglycemic clamps, glucose flux 
analysis, and isolated muscle glucose uptake after the 3 week Rlx or Vehicle 
intervention in HF-fed mice. (A) Glucose infusion rate (top) and arterial 
glucose (bottom) during the insulin clamp. Mice were fasted 5 h prior to the 
onset of the clamp. Blood glucose was maintained at ~150 mg/dL during 
steady-state (80-120 min) and the time course is displayed to demonstrate 
quality of the clamp. 50% glucose was infused to maintain euglycemia. 
Endogenous glucose production and whole-body glucose disposal (B-EndoRa 
and Rd) during the insulin clamp. Basal values are an average of t= -15 and -5 
min and the insulin clamp values are an average of 80-120 min (steady-state).  
(C) Glucose metabolic index (Rg) after the insulin clamp in the gastroc 
(gastrocnemius), SVL (superior vastus lateralis), and heart. Isolated muscle 
glucose uptake (D) on the soleus and EDL (extensor digitorum longus). Mice 
were fasted for 5 h prior to muscles being excised.  Data are expressed as mean 
± SE, n= 11-13,*P-value ≤ 0.05. 
95 
 
  
Figure 4.8 - Protocol 2: Insulin signaling and immunohistochemical stain of 
skeletal muscle and liver. Western blot analysis of the activation status of Akt 
(A) analyzed as the ratio of phosphorylated Akt to total Akt in liver (top) and 
skeletal muscle (bottom) from protein extracted from mice after the insulin 
clamp (V-vehicle and R-relaxin). Immunohistochemical detection of skeletal 
muscle collagen-III (B) and collagen-IV (C) from the gastrocnemius muscle. 
Immunohistochemical detection of hepatic collagen-III (D). 
Immunohistochemical analysis was performed on tissues fixed immediately 
following the insulin clamp. AU represents arbitrary units. Data are expressed as 
mean ± SE, n= 5-6,*P-value ≤ 0.05. 
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Figure 4.9 - Protocol 2: Collagen protein levels and SMAD2 signaling in cardiac 
muscle. Immunohistochemical detection of collage-III (A) and –IV (B) from 
hearts fixed after the insulin clamp. Western blot analysis of phospho-SMAD2, 
total SMAD2, and the ratio of phospho to total SMAD2 (C) from cardiac protein 
extracts after the insulin clamp. AU represents arbitrary units. Data are expressed 
as mean ± SE, n= 5-6,*P-value ≤ 0.05. 
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  Figure 4.10 - Protocol 2:  Capillarity density and vascular reactivity in response 
to the Rlx intervention. Capillary density (A) quantified with 
immunohistochemical staining of CD-31. Capillary density is quantified as the 
number of CD-31+ cells. Plasma vascular endothelial growth factor (VEGF) 
concentration (B) after the insulin clamps. Vascular reactivity (C) from excised 
aortas after the insulin clamps. Endothelial-dependent relaxation (left; 
carbachol), smooth muscle-dependent relaxation (middle; sodium nitroprusside), 
and stress generated from phenylephrine (right; PE). Responses represented as a 
percent of maximal tension from KCl stimulation. Data are expressed as mean ± 
SE, n= 5-8,*P-value ≤ 0.05. 
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Chapter V 
 
CELLULAR BASIS FOR IMPAIRED ENDOTHELIAL INSULIN TRANSPORT 
SYSTEM IN THE SKELETAL MUSCLE MICROVASCULATURE OF HIGH 
FAT-FED C57BL/6J MICE 
 
Aims 
Insulin resistance and impaired vascular insulin signaling is associated with a 
blunted delivery of insulin to the interstitium of skeletal muscle limiting the interaction 
with the insulin receptor (48). The Barrett Laboratory has investigated the transport 
mechanisms of insulin across the endothelial capillary barrier (23, 27, 33). These studies 
have characterized the binding of insulin to the capillary wall, a delayed delivery to the 
muscle interstitium in vivo, dependence of caveolin-1 for transendothelial insulin 
transport in vitro, and shown that stimuli that induce insulin resistance (e.g. TNFα) 
decrease  insulin transport and caveolin-1 expression in vitro (33, 34, 164). Cavoelin-1 is 
the critical protein for the formation of caveolae. The elegant investigations performed by 
the Barrett Laboratory describe the transport of insulin via a receptor mediated process. 
However, a limitation to these studies is that the mechanistic work was performed 
utilizing bovine aortic endothelial cells. It is currently unknown whether stimuli that 
create skeletal muscle insulin resistance, such as a HF diet, cause structural changes to 
the capillary wall that may hinder insulin transport. The hypothesis tested in Chapter V 
was that 16 week HF-fed mice will have a decrease in caveolae number within the 
endothelial cell layer of skeletal muscle capillaries. 
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Introduction 
The capillary network in skeletal muscle forms tight junctions with an enrichment 
of caveolae, which contrasts from the liver that is comprised of a discontinuous 
endothelium that permits greater exchange of macromolecules (27). This suggests that the 
transport of insulin is specific to the tissue of interest and that transport may be limiting 
in a tissue such as skeletal muscle (or adipose with a similar capillary architecture), but 
not in a tissue more adept to transport of large macromolecules such as the liver.  
A primary transport mechanism for the movement of macromolecules across tight 
capillaries is endocytosis and secretion via a caveolae dependent process. Schubert et al. 
showed that caveolae-deficient endothelial cells are incapable of transporting albumin in 
vivo, as the endothelial cells were unable to endocytose albumin for transport (165). 
Notably, only one study has comprehensively characterized the role of insulin transport 
in vivo. The study was performed in rat cardiac muscle and established a receptor 
mediated transendothelial transport mechanism (166). This study has not been expanded 
to other insulin sensitive tissues. Schutzer et al. demonstrated a decline in caveolin-1with 
aging, a risk factor for the development of insulin resistance, in a smooth muscle cell line 
(167). However, the effect of aging on the endothelial caveolae structure was not 
investigated. 
The goal of Chapter V was to visualize the capillary endothelial caveolae 
architecture in vivo. Specifically, Chapter V was designed to determine whether 16 week 
HF-fed mice (that are insulin resistant) have alterations in caveolae number or size in 
single endothelial layer capillaries that perfuse skeletal muscle utilizing transmission 
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electron microscopy (TEM). This study is a first step in bridging the in vitro work 
performed (33, 34, 164) to animal models of insulin resistance suggesting the importance 
of transendothelial insulin transport to skeletal muscle insulin action. The hypothesis 
tested was that diet-induced insulin resistant mice have fewer endothelial caveolae 
compared to low fat chow-fed controls.  
 
Experimental Design 
C57BL/6J mice were fed a chow or HF diet for 16 weeks. Mice were studied at 
20 weeks of age. At the termination of the diet mice underwent perfused fixation as 
described in Chapter II and the right red gastrocnemius was excised. The samples were 
further processed for TEM staining by the Vanderbilt University Cell Imagine Shared 
Resource Core. Visualization is described in detail in Chapter II.  
 
Results 
Mice fed the 16 week HF diet gained significant body weight and fat mass 
compared to the age-matched, chow-fed controls (Table 5.1).  Qualitative analysis of 
caveolae density has been performed. Micrographs were randomized, labels removed, 
and then separated based on the caveolae density within the capillary. The micrographs 
were separated into chow-fed and HF-fed groups. This initial screen permitted the 
decision to move forward with specific quantification of caveolae area per endothelial 
cell area with an inclusion criterion of greater than 80% success of the qualitative 
analysis, which was accomplished. There was a striking reduction in caveolae number in 
the HF-fed group compared to the chow-fed mice (Figures 5.1 and 5.2).  
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Discussion 
The TEM studies indicate that diet-induced insulin resistant mice have fewer 
caveolae within the endothelial layer of the capillary compared to chow-fed controls. I 
speculate this microstructural adaptation in the HF-fed mice provides a low insulin 
transport capacity environment compared to lean mice with capillaries enriched with 
caveolae. This low transport state is consistent with the in vitro findings from Barrett and 
colleagues (34) that indicated inflammatory cytokines decrease the expression of 
caveolin-1 and the transendothelial transport of insulin.  
The strength of TEM is that it allows for tissue collection by perfusing a fixative 
that maintains capillary integrity giving a representation of the in vivo capillary 
architecture. The current data can only be extrapolated and applied to the concept of 
insulin transport within skeletal muscle. The experiments were not designed to visualize 
insulin localization within caveolae and future investigation will address this limitation. 
There is clearly a qualitative reduction in endothelial caveolae in HF-fed mice. The 
current experiments will be expanded in future studies to be more quantitative so that we 
may determine whether there are significant differences in caveolae per capillary area in 
our model.  
The paradigm of insulin delivery in skeletal muscle is not without controversy 
(27). The initial work used bovine aortic endothelial cells or umbilical vein endothelial 
cells. The caveat to applying transport techniques to venous endothelium is that venous 
cells are innately leaky when compared to aortic or arterial endothelium, thus the 
potential for false transport data.  
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The transport assays performed by Barrett’s Laboratory (33, 34, 164) were 
performed in cell culture without in vivo validation. Furthermore, the TEM technique we 
applied can be expanded by injecting labeled insulin into mice and visualizing whether 
insulin is specifically endocytosed and localized within caveolae structures. The potential 
of confocal microscopy in live animals could allow for visualization of insulin transport; 
however, a caveat to this technique is the visualized muscle is superficial limiting the 
access to nutrient blood flow. The current state of the insulin transport field is limited and 
critical data for basic characterization of the mechanisms of insulin transport in skeletal 
muscle remains to be elucidated.  
These preliminary findings suggest a potential link between skeletal muscle 
insulin resistance, transendothelial insulin transport, and caveolae density. The basic 
process of tissue specific insulin transport needs further characterization. The 
understanding of how insulin transverses the capillary barrier to reach skeletal muscle 
insulin receptors could provide a novel pharmacological target to treat insulin resistance 
and more complete understanding of the pathogenesis of skeletal muscle insulin 
resistance.  
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Table 5.1 
Mouse body weight and composition 
 
Chow-Fed HF-Fed 
N 3 3 
Body Weight (g) 25.8 ± 0.9 47.3 ± 1.5* 
Fat Mass (%) 4.9 ± 0.4 35.4 ± 4.0* 
Lean Mass (%) 76.4 ± 0.4 53.9 ± 2.9* 
Data are expressed as mean ± SE. *P-value ≤ 0.01 
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A B 
Figure 5.1 – Transmission electron micrograph from the red gastrocnemius of 
chow-fed (A) and 16 week HF-fed (B) mice. Arrows indicate single endothelial 
capillary. Images were acquired at a magnification of 11,000x.  
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Figure 5.2 – Transmission electron micrograph from the red gastrocnemius of 
chow-fed (A) and 16 week HF-fed (B) mice. Red arrows indicate single 
endothelial capillary and blue arrows indicate a single caveolae. Micrographs are 
the same capillaries from Figure A.1. Images were acquired at a magnification of 
67,000x.  
 
A B 
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Chapter VI 
 
SUMMARY 
 
Collectively the data presented within the Dissertation show the significant 
contribution of vascular function, capillary density, and capillary architecture to skeletal 
muscle insulin resistance. The genetic induction of capillary rarefaction in Chapter III 
showed that the decrease in capillary density within insulin resistant skeletal muscle is a 
direct cause of the diseased muscle and models that induce muscle capillary proliferation 
ameliorate skeletal muscle insulin resistance. Furthermore, therapeutic application of the 
vasoactive and extracellular matrix remodeling hormone relaxin, in Chapter IV, reduced 
the extramyocellular barriers to insulin-stimulated MGU, which are exacerbated in 
insulin resistant states. Chapter V demonstrated gross reductions in caveolae density 
within skeletal muscle endothelium of obese mice. The diminished caveolae number 
could contribute to the pathogenesis of skeletal muscle insulin resistance; however, the 
role of caveolae in insulin transport to muscle interstitium needs further investigation. 
These data provide an opportunity for investigation of novel therapeutic targets to treat 
the underlying vascular dysfunction with the goal to simultaneously intervene to 
ameliorate the greater metabolic syndrome associated with obesity.  
The correlation between functional and structural capillary rarefaction to skeletal 
muscle insulin resistance has been well established. To date there has been no evidence 
directly linking structural capillary rarefaction to the pathogenesis of insulin resistance. 
These are the first studies to show the causative role of changes in capillary density to the 
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development of skeletal muscle insulin resistance. Notably, the mouse model investigated 
within Chapter III took advantage of tissue specific cre-lox recombination technology to 
specifically ablate VEGF-A from skeletal and cardiac muscle without the complications 
of a high fat diet (e.g. weight differences, tissue fat accumulation). This mouse model 
facilitated the direct investigation into the role of capillary rarefaction in the development 
of skeletal muscle insulin resistance. The phenotype in the VEGF-deficient mice 
emphasizes the significance of capillary rarefaction to the early progression of skeletal 
muscle insulin resistance.  
The comparison between in vivo and ex vivo insulin action was important to 
corroborate that the loss of the vascular delivery component of MGU caused the 
impairment in insulin-stimulated glucose uptake in Chapter III.  This comparison 
indicated that the phenotype was not driven by an off target effect due to the genetic loss 
of muscle VEGF directly impairing myocellular insulin action. There are limitations to 
this conclusion. Indeed assessing insulin action ex vivo removes the delivery component 
of MGU and focuses on the direct effects of the genetic loss of capillaries on myocellular 
insulin action; however, the absence of blood flow is more complex than uptake that is 
reliant solely on diffusion. Evidence from our laboratory suggests an important regulatory 
role of the extracellular matrix-integrin interaction, which may not be active in the ex 
vivo setting. Additionally, endocrine and nutritional factors that may interact with the 
insulin signaling pathway and glucose uptake are absent in this model. It would be 
necessary to monitor the plasma to interstitial gradient of glucose and insulin to 
conclusively determine that there was a detriment in glucose and insulin delivery to 
skeletal muscle during the insulin clamps. Though unlikely, the ex vivo loss of multiple 
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extramyocellular factors may overemphasize the contribution the capillary density to a 
decrease in vascular delivery of glucose and insulin to our model.  
The muscle creatine kinase promoter driving the expression of cre-recombinase in 
Chapter III is expressed in skeletal and cardiac muscle. The loss of cardiac VEGF-A 
induced compensation in the heart to maintain cardiac output. The equivalent cardiac 
output between genotypes was critical to the interpretations and conclusions of Chapter 
III. Changes in cardiac output can affect downstream muscle perfusion and delivery of 
molecules. Delivery is based on muscle blood volume and blood flow velocity, and a 
detriment in cardiac output would likely cause a subsequent decrease in both. The 
compensatory mechanisms, present in the skeletal and cardiac muscle VEGF-A deficient 
mice, to maintain cardiac output are unknown and could potentially contribute to the 
peripheral impairment in insulin action. Cardiac compensation and failure is associated 
with insulin resistance. A possible mechanistic link between peripheral insulin resistance 
and cardiac adaptations are elevated catecholamine levels (168). To optimize our 
experimental setup a more specific cre-recombinase promoter could be utilized with the 
VEGF-A
lox/lox
 mice. Recently McCarthy et al. developed a cre-recombinase mouse strain 
with an inducible human α-skeletal actin promoter that is not active in cardiac muscle 
(169). This technology would permit the investigation of skeletal muscle specific 
capillary rarefaction, thus eliminating the potential confounding factor of the cardiac 
phenotype in my model. Furthermore, the inducible system more closely mimics the 
pathological state of capillary rarefaction and limits any compensatory mechanisms as the 
recombination would occur in adult animal.  
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The influence of capillary density in skeletal muscle insulin action needs further 
investigation, particularly in different physiological states. The benefits of exercise and 
lifestyle changes to obesity related insulin resistance has long been established. 
Moreover, the importance of skeletal muscle capillary supply is critical to exercise 
capacity. Exercise training induces muscle capillary expansion, which is regulated by 
muscle VEGF secretion (170). By employing our mouse model, key mechanistic links 
between exercise, capillary density, and skeletal muscle insulin action could determine 
whether the metabolic benefits of exercise in skeletal muscle are dependent on an 
augmentation of capillary density induced by VEGF. This experiment would provide 
insight into the potential efficacy of treating insulin resistance skeletal muscle with a 
vascular proliferative agent.  
Though lifestyle changes such as exercise and diet are recommended for 
treatment of obesity related metabolic disease, compliance to this prescription is low. 
There is demand for comprehensive therapeutic options to combat the low adherence to 
exercise and diet prescription to treat metabolic and vascular disorders, as these co-
morbidities associate with obesity. The pleiotropic hormone relaxin targets multiple 
physiological systems, including the vasculature and extracellular matrix, to benefit 
vascular and metabolic dysfunction present in HF-fed mice (Chapter IV). This 
physiological approach to the treatment of insulin resistance provides a novel avenue to 
investigate the potential to target the extramyocellular barriers to MGU. Our laboratory 
and others have demonstrated that genetic and pharmacological interventions targeting 
the extracellular matrix and vasculature ameliorate diet-induced insulin resistance (86, 
87, 171). 
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The hemodynamic action of relaxin is well established. The data presented in 
Chapter IV was the first to test the vascular effect in skeletal muscle. An acute 
administration in lean mice resulted in enhanced skeletal muscle perfusion and insulin-
mediated MGU. Notably, the acute vasodilatory and metabolic response to relaxin was 
absent in HF-fed mice. The complex regulation of the vasoactive response to 
pharmacological administration of relaxin converges on activation of eNOS and synthesis 
of nitric oxide (145). However, obese clinical patients and animals models have an 
impaired response to eNOS activators. This dysfunction is likely the basis of the non-
response in the acute relaxin infusion, HF-fed cohort. Importantly the chronic 
intervention with relaxin proved to be efficacious in improving vascular and metabolic 
function present in the HF-fed mice (Protocol 2; Chapter IV). The dependence on 
treatment duration is consistent with hypertensive rat models (146).  
The treatment effects of relaxin in our model were dependent on the duration of 
administration. The expansion in skeletal muscle capillary density and improvement in 
endothelial specific vasodilation, decreasing the extramyocellular delivery barrier to 
MGU, are mechanisms that require chronic relaxin exposure. The angiogenic response 
requires longer than the 6.5 h infusion duration in Protocol 1 of Chapter IV, thus the 
remodeling effects evident with long-term treatment were necessary for the outcomes in 
Protocol 2 of Chapter IV. The coupling and phosphorylation state of aortic eNOS in our 
model, surrogates for the functional state of eNOS, are unknown. The studies performed 
in Chapter IV utilized aortic ring reactivity to measure endothelial function. Aortic ring 
reactivity provides a more physiological assessment of eNOS function than the 
biochemical analysis of eNOS coupling and phosphorylation. The analysis of the 
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coupling and phosphorylation state of eNOS before and after treatment could be an 
important next step in understanding the mechanisms by which relaxin improves 
endothelial-dependent relaxation.  
The improvement in glucose flux during the insulin clamps (Protocol 2; Chapter 
IV) was not limited to skeletal muscle. Hepatic glucose production was suppressed to a 
greater extent in response to hyperinsulinemia after the 3 week relaxin treatment. This is 
an important result as hepatic insulin resistance and excessive glucose production 
contributes to the pathogenesis of type 2 diabetes. The mechanism of action for the 
enhancement in hepatic insulin action is not fully elucidated. The glucoregulatory effects 
of the relaxin intervention at the liver and skeletal muscle are likely independent 
mechanisms. The liver is composed of a highly perfused, discontinuous capillary network 
facilitating rapid and efficient exchange of hormones and macromolecules. However, the 
extracellular matrix remodeling phenotype in the liver is speculated to contribute to the 
mechanisms for the improvement in hepatic insulin action. Kang et al. has described the 
significant interaction between collagen and cell surface integrin receptors in regulating 
insulin action (87). The dichotomous action of relaxin on liver and skeletal muscle 
glucose flux highlights the pleiotropic effects of the hormone on multiple physiological 
systems. The broad actions of relaxin make it a possible candidate to treat metabolic and 
cardiovascular dysfunction induced by obesity.    
The studies performed in Chapter III and IV could have benefited from a direct 
measurement of skeletal muscle blood volume and muscle interstitial insulin 
concentration. The insulin clamp technique relies on a constant rate of insulin infusion for 
2.5 h to maintain postprandial plasma concentrations. The subsequent rise in plasma 
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insulin concentration during the clamp recruits unperfused capillaries and increases total 
limb blood flow (45, 84, 137, 141, 142, 172). Microvascular recruitment and skeletal 
muscle blood volume are affected by capillary density and the response in total limb 
blood flow is dependent on insulin induced eNOS activation (37, 44, 49, 58, 59, 67). 
Kubota et al. demonstrated in models of impaired endothelial insulin signaling and diet-
induced insulin resistance that mice have a blunted increase in muscle blood volume and 
interstitial insulin concentration during an insulin clamp (48). Notably, the detriment in 
muscle capillary blood volume, interstitial insulin, and subsequent impaired peripheral 
glucose disposal was reversed by chronic infusion of an eNOS dependent vasodilator 
(48). Moreover, insulin clamps in normal conscious dogs revealed that lymph insulin, a 
marker for the interstitial concentration, remained lower through the duration of the 
clamp at a ratio of 3:2 (28). Together these studies provide evidence for the importance of 
insulin delivery to the muscle and that impairments in the hemodynamic action of insulin 
can delay or attenuate the rise in interstitial insulin during an insulin clamp. Interstitial 
insulin more strongly correlates to the onset of peripheral glucose uptake than plasma 
insulin. One can postulate that the loss of vascular function in Chapter III may hinder the 
rise in interstitial insulin and that the gain of function in Chapter IV may have enhanced 
it.  
Skeletal muscle angiogenesis is a complexly regulated process involving several 
growth factors. The primary stimulus and driver for capillary growth and sprouting is 
VEGF. The tightly regulated process becomes abnormal in obesity and diabetic states. 
Though many report an elevation of VEGF expression in diabetes, there is a concordant 
elevation of anti-angiogenic factors such as the adipokine thrombospondin-1, 
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dysregulation of soluble VEGFR1 secretion, vasohibin-1, and impaired VEGFR2 signal 
transduction (173-175). The imbalance of pro- and anti-angiogenic factors associated 
with diabetes results in a weakened response to cardiac and peripheral ischemia that may 
culminate in heart disease, limb amputation, and other disorders. Vasoactive compounds 
that can overcome this angiogenic dysregulation may reduce mortality and morbidity 
associated with diabetes. Relaxin elevated plasma VEGF, shown in Chapter IV, and may 
switch the balance towards a pro-angiogenic environment leading to skeletal muscle 
capillary preservation and expansion. It is important to note that excessive VEGF 
signaling can be detrimental to skeletal muscle morphology. Viral delivery of VEGF in a 
rabbit model of hindlimb ischemia promoted long-term angiogenesis and increased 
muscle perfusion; however, the unregulated angiogenic stimulus induced skeletal muscle 
fibrosis and increased skeletal muscle macrophage intravasation (176). A potential 
approach to combat the aberrant angiogenesis in the setting of excessive VEGF is the co-
expression of angiopoietin-1 (ang-1). Ang-1 is critical for capillary maturation and 
integrity. The administration of VEGF and ang-1 directly into ischemic skeletal muscle 
resulted in greater collateral vessel development, capillary density, and a decrease in the 
incidence of necrosis compared with either VEGF or ang-1 alone (177). The application 
of pro-angiogenic therapeutic agents to skeletal muscle must take into account the 
coordinated regulation and maturation of capillary development. 
A contrast in circulating VEGF existed between the results of Chapter III and IV. 
The diet-induced insulin resistant mice in Chapter IV had greater plasma VEGF levels 
compared with the lean mice in Chapter III, consistent with previous investigations (175). 
The capillary rarefaction present in the muscle-specific VEGF knockout animals was 
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induced by the absence of muscle tissue VEGF expression. Tissue expression of VEGF is 
essential for normal capillary development and maintenance. The genetic deletion of 
VEGF occurred at gestational day 16. The mVEGF
-/-
 mice of Chapter III likely were born 
with fewer capillaries perfusing skeletal muscle that was conserved through adulthood. 
Interestingly there was no difference in circulating VEGF; however, there was an 
elevation in circulating VEGF after the relaxin intervention that likely contributed to the 
expansion of capillary density (Protocol 2; Chapter IV). The equivalent plasma VEGF in 
the genetic models in Chapter III provides a survival signal for the vascular networks 
present (78), whereas the increased plasma VEGF after the 3 week relaxin intervention 
provides a pro-angiogenic environment for the expansion and preservation of skeletal 
muscle capillary density in HF-fed mice. 
The transport of insulin to the skeletal muscle interstitium and the contribution of 
caveolae to capillary transendothelial transport is a poorly understood phenomenon. 
Barrett and colleagues (33, 34, 164) showed promising in vitro work indicating the 
critical role of caveolae to insulin delivery and localization of the insulin receptor within 
these microstructures of the endothelial wall. The novel aspect of the studies performed 
in Chapter V were the comparison between a lean, healthy mouse and an obese, insulin 
resistant mouse while using a perfused fixation technique to maintain in vivo capillary 
architecture. The results of Chapter V support previous in vitro work performed that 
implicated insulin resistant inducing stimuli, such as proinflammatory cytokines, to the 
blunted transport of insulin across the endothelium and the decreased expression of the 
essential protein for caveolae formation, cavoelin-1 (34). The characterization of skeletal 
muscle capillary structure and potential transport capacity is important to the 
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development and progression of the pathogenesis of skeletal muscle insulin resistance. 
Further investigation needs to corroborate the dependence of transcellular transport of 
insulin across skeletal muscle capillary endothelial cells for delivery. This is the first 
characterization of capillary caveolae content in lean and obese mice and supports the 
need for further research to the mechanism of insulin delivery.  
A strength of the work presented in this Dissertation is the emphasis on in vivo 
analyses and the use of animal models of disease. The components of insulin-mediated 
glucose and insulin delivery are impossible to examine with ex vivo and in vitro 
experimental approaches. These experiments over emphasize the role of insulin action 
specifically at the myocyte, which include the steps for glucose transport and 
phosphorylation. The current work comprehensively addresses the significant 
contribution of skeletal muscle capillary density to the etiology of insulin resistance and 
the potential for targeting the extramyocellular barriers to MGU to rescue diet-induced 
insulin resistance. The data presented is consistent with previous reports from our 
laboratory and others that demonstrate a strong relationship between capillary density and 
insulin action (53, 54, 86, 87, 171). More specifically, pharmacological and genetic 
interventions that prevent or reverse the onset of diet-induced skeletal muscle insulin 
resistance also have greater muscle capillary density.  The vasodilatory action of insulin 
and the capillary reserve present in skeletal muscle are viable treatment targets for 
skeletal muscle insulin resistance. 
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Chapter VII 
 
CONCLUSIONS AND IMPLICATIONS 
 
The data that comprise this Dissertation support the paradigm that the 
extramyocellular barriers to insulin-stimulated MGU are essential to the pathogenesis of 
insulin resistance and provide novel therapeutic targets. These barriers involve the 
physiological regulation of processes that influence hormone and substrate delivery, such 
as capillary density, vascular function, extracellular matrix remodeling, and endothelial 
caveolae density. The fundamental conclusions of the cumulative work include: capillary 
rarefaction is significant to the pathogenesis of skeletal muscle insulin resistance, the 
vasoactive and extracellular matrix remodeling hormone relaxin rescues diet-induced 
insulin resistance, and a deficiency in caveolae microstructure density is present within 
the endothelial layer of the skeletal muscle capillaries in HF-fed mice.  
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